header logo image


Page 29«..1020..26272829

Archive for February, 2021

Women’s Menstrual Cycles Tied to Moon’s Phases – HealthDay News

Monday, February 1st, 2021

THURSDAY, Jan. 28, 2021 (HealthDay News) -- There have long been theories that women's menstrual cycles align with the moon, and now a new study suggests there's some truth to that.

Using years of records kept by 22 women, researchers found that for many, menstrual cycles "intermittently" synced up with the phases of the moon.

The link happened only about one-quarter of the time for women aged 35 or younger, and just 9% of the time for older women. There was a great deal of variance, though, among individuals.

And for a few women, there were hints that excessive exposure to artificial light at night could have thrown off any moon-menstruation synchrony.

One expert called the findings "interesting," and said they might reflect remnants of a lunar influence that benefited humans' ancient ancestors.

Early primates were nocturnal creatures, so a degree of moon-influenced behavior would make sense for them, according to Deena Emera.

Emera, who was not involved in the study, is an evolutionary geneticist based at the Buck Institute's Center for Reproductive Longevity and Equality, in California.

Mating is risky business, Emera noted, as it makes animals vulnerable to predators. So mating during the new moon, under cover of more darkness, would be a "reasonable strategy," she said.

That also means there would be an advantage to ovulation being timed to the new moon.

"I think any [moon-menstruation] synchronization seen today is probably a relic of an ancient primate trait," Emera said.

She also stressed that women need not worry if their menstrual cycles are not wedded to the moon.

"We're so different from those early rodent-like primates," Emera said. "We certainly don't need to sync our cycles to the moon to successfully reproduce."

The study, published online Jan. 27 in the journal Science Advances, is far from the first to investigate moon-menstruation correlations.

The most obvious one is that both lunar and menstrual cycles are roughly one month long. But research dating back to the 1950s has suggested other links: Women were found to commonly start their periods around the time of the full moon. That would mean ovulation happened near the new moon, two weeks before.

However, relatively more recent studies uncovered no such links.

"I was puzzled by the discrepancy between these quite old results and later studies," said Charlotte Helfrich-Frster, the lead researcher on the new study. She's chair of neurobiology and genetics at the University of Wrzburg, in Germany.

Helfrich-Frster's team took a different approach. Instead of studying a large group of women and looking for broad patterns, they had 22 women keep menstruation diaries, which they did for an average of 15 years, and up to 32 years.

Among women aged 35 or younger, the researchers found, menstrual periods synced up with the moon phases about 24% of the time. But the women varied widely: Some were aligned with the moon more often than not, while others never were.

Three women in the "never" category also reported substantial exposure to artificial light at night.

However, Helfrich-Frster said, it's not possible to say whether the bright lights of modern life have disrupted any synchrony between women's cycles and the moon.

Like Emera, she framed the findings in evolutionary terms, but within human history.

Long ago, Helfrich-Frster said, it would have been prudent to stay inside on dark new-moon nights. And why not use that time to mate? In theory, she explained, women who regularly ovulated around new-moon time would have more children and "spread their genes that inherit the timing to the moon."

When it comes to links between lunar rhythms and reproduction, many studies have found them in sea animals, said Satchidananda Panda, an adjunct professor of biological sciences at the University of California, San Diego.

But, he said, that is seen only rarely in today's primates.

Panda said the current study "opens up another line of scientific investigation on biological rhythms."

He also speculated that in humans, the moon might indirectly influence menstrual cycles.

"For example," Panda said, "many cultural activities in ancestral societies, or even in modern-day Asia and Africa, are on full-moon days or tied to the lunar cycle."

Certain foods consumed during those events, like soybeans, might affect hormonal activity, he added.

More information

The U.S. Department of Health and Human Services has more on the menstrual cycle.

SOURCES: Charlotte Helfrich-Frster, PhD, chair, neurobiology and genetics, University of Wrzburg, Germany; Deena Emera, PhD, Center for Reproductive Longevity and Equality, Buck Institute, Novato, Calif.; Satchidananda Panda, PhD, adjunct professor, biological sciences, University of California, San Diego, and professor, Salk Institute, La Jolla, Calif.; Science Advances, Jan. 27, 2021, online

Originally posted here:
Women's Menstrual Cycles Tied to Moon's Phases - HealthDay News

Read More...

Is The Full Moon Affecting Your Sleep and Flow? – Longevity LIVE – Longevity LIVE

Monday, February 1st, 2021

Specifically, the study found that in women aged 35 or younger, their cycles synced up with the moon phases about 24% of the time. That said, the researchers also noted that synchronization slowly disappeared over time as the women grew older, and found that the link lessened as a result of increased exposure to artificial light.

It appears that menstrual cycles arent the only thing that can be altered or affected by the moon.

The study, published on the 27th of January, involved researchers analyzing the sleep patterns of 98 people from the Toba Indigenous communities located in northeast Argentina. One group was rural, with no access to electricity, the second had limited access to electricity and the third was located in an urban setting with full access.

According to study co-author, Horacio de la Iglesia, their reason for this was because they are all ethnically and socioculturally homogeneous, so it has become an outstanding opportunity to address questions about sleep under different levels of urbanization without other confounding effects.

In addition to collecting data through the use of sleep-monitoring wrist devices, the researchers also used sleep data from 464 college students in the Seattle area. It should be noted that the college student data had been originally collected for a separate study.

See the original post here:
Is The Full Moon Affecting Your Sleep and Flow? - Longevity LIVE - Longevity LIVE

Read More...

Calico Purring Right Along With Life Extension Research – Nanalyze

Monday, February 1st, 2021

Earlier this month, Alphabet (GOOG) took the air out of its Loon subsidiary, a former moonshot project for deploying internet around the world using high-flying balloons. Apparently, the economics just didnt work out. No word on how much Googles parent company spent on Loon, but SoftBank had sunk $125 million into the business in 2019. This seems like the latest sign that the tech giant is tightening its belt a bit in an increasingly risky regulatory environment. That made us wonder whats happening with another venture that isnt contributing anything to its bottom line. Lets dive into Calico, a subsidiary focused on life extension research and development.

Calico is pretty much the opposite of Verily Life Sciences, the Alphabet unit working to digitize healthcare in every possible way. Verily is one of the few companies that does generate some revenue among the $461 million that its sideline subsidiaries earned through the first nine months of 2020. Some of the joint ventures connected to Verily are developing apps or new medical devices, with a certain amount of publicity and transparency. Calico operates more like a nonprofit research center thats secretly working on some biotech version of the Manhattan Project, so most of what we read is pretty superficial and saccharine.

At face value, Calico is pure anti-aging R&D, starting at the very beginning of the problem with what is aging? For example, one of its public-facing projects involves studying how yeast ages, apparently without in situ experiments involving a teenagers room. The premise (in very broad strokes) is that if we can understand how yeast age at the cellular level, we could all one day look like Brad Pitt forever. But the biggest news to emerge is that Calico scientists created a bit of new technology to help analyze the yeast cells, enabling genome-wide characterization of the aging process, which certainly sounds significant and was published in a peer-reviewed journal.

The Miniature-chemostat Aging Device (MAD) purifies 50 million old cells in a single test tube to speed up the search for genetic biomarkers of aging. An additional platform that sounds similar to the technology used in lab-on-a-chip solutions developed by companies like Berkeley Lights (BLI) allows scientists to observe the entire aging process in single cells hundreds of thousands each week allowing them to screen for lifespan-extending modifications that can increase the yeast lifespan beyond that of your ordinary lab yeast. The company integrated computer vision and machine learning to recognize cell division from time-lapse images or to measure the age of a cell directly from static images.

While a new cell-counting gizmo using AI sounds great, thats certainly not something out of reach for any large research university. Calico is a company that has at least $2.5 billion in funding thanks to its most high-profile partnership with AbbVie (ABBV), a pharmaceutical company with a market cap of nearly $200 billion as of late January 2021.

The companies first joined forces in September 2014. Three years later, Calico and AbbVie had already burned through $1 billion, but that didnt stop the duo from extending their research collaboration and kicking in another $500 million each, according to the San Francisco Business Times. So you would think theres some high-pressure expectation to produce an anti-aging Brad Pitt pill or something significant. What has all that money produced? According to the company, the partnership has resulted in two dozen early-stage programs addressing disease states across oncology and neuroscience and new insights into the biology of aging.

The 2018 deal makes Calico responsible for research and early development until 2022 and for advanced collaboration projects through Phase 2a clinical trials through 2027. In fact, theres actually a whisper of something finally gaining traction. Endpoints News was the first to report that a team from Calico and AbbVie is conducting a phase 1 safety study to test a drug called ABBV-CLS-579 for treating solid tumors. The article also noted how one of the companys principal investigators just published a paper in Nature on how Calico is using AI to predict genome folding from DNA sequence alone.

Calico is mining for answers to longevity in human DNA by creating its own hardware and software to automate and accelerate that search. One of its other high-profile ventures, in fact, involved mining the genetic database of Ancestry.com for three years. The Holy Grail was to find genetic commonalities among those who live longer, but research delivered some unexpected results. Another study based on the Ancestry data in another prestigious journal, Genetics, found that while longevity runs in families, DNA isnt as strong an influence on how long an individual lives, so just because Grandpa Joe lived to 103 doesnt mean youre going to outlive a lifetime of junk food.

Other ongoing collaborations include the Broad Institute of MIT and Harvard, the Buck Institute for Research on Aging, and C4 Therapeutics (CCCC), a small-cap biotech company focused on treating diseases of aging, including cancer, by degrading proteins known to drive disease.

Pretty much every story on Calico refers to the fact that the former Genentech CEO Art Levinson, who has a PhD in biochemistry, is in charge of the Alphabet subsidiary. Acquired by Roche for nearly $47 billion about a dozen years ago, Genentech was considered the worlds oldest and most successful biotechnology company. Its also worth noting that he serves on the boards of Apple and the Broad Institute, as well as formerly served on the boards of small-cap biotechs, including Amyris Biotechnologies, a synthetic biology stock. He is also an advisor on a bunch of scientific boards. So the assumption is that this guy knows what hes doing in terms of his scientific expertise needed to lead one of the most well-funded, private, anti-aging R&D labs in the world.

As we told you more than five years ago, Calico will likely forever be an innovation lab similar to Alphabets DeepMind AI lab in London. The only thing close to a pure-play in the longevity theme is perhaps C4 Therapeutics, which has developed a novel platform for harnessing the bodys natural mechanisms for regulating protein levels to fight diseases of aging. But the Boston area biopharmaceutical company is on pace to double its losses in 2020 from 2019, and it gets all of its revenue from collaboration agreements like the one with Calico. Well just have to wait for a Brad Pitt pill and make our money on the market the old-fashioned way over time.

Pure-play disruptive tech stocks are not only hard to find, but investing in them is risky business. That's whywe created The Nanalyze Disruptive Tech Portfolio Report, which lists 20disruptive techstocks we love so much weve invested in them ourselves. Find out which tech stocks we love, like, and avoid in this special report, now available for all Nanalyze Premiumannual subscribers.

Go here to read the rest:
Calico Purring Right Along With Life Extension Research - Nanalyze

Read More...

Dr. William Kelley inducted into IAOTPs Hall of Fame – PRUnderground

Monday, February 1st, 2021

Dr. William N. Kelley, MACP, MACR, Professor of Medicine at the University of Pennsylvania, was recently inducted into the International Association of Top Professionals (IAOTP) Hall of Fame.

Being selected by the International Association of Top Professionals is an esteemed honor, as only 20 IAOTP members are inducted each year into the exclusive Hall of Fame. These special honorees are distinguished by their longevity in their fields, the contributions they have made to society, and the impact they have had on their industries.

With over five decades of professional experience as an Educator, Physician Scientist, and Medical Doctor, Dr. Kelley has undoubtedly proven himself an extraordinary professional and an expert in medical research and education. Dr. Kelley is a dynamic, results-driven leader who has demonstrated success as one of the most respected doctors in America. In the early 1990s at PENN, Dr. Kelley, in his role as Dean of the Medical School and CEO of the Health System (the combination now known as PENN Medicine), began to build a broad research program focused on the creation of gene-based medicine and vaccines as a new method for preventing and curing human disease. While the road was a rocky one over the last three decades, he is proud to note that PENN Medicine is now the global leader in this new field. This includes the two recently FDA approved mRNA vaccines (Moderna and Biontech/Pfizer) to prevent COVID-19 which came from the PENN Medicine research laboratories of Doctors Katalin Kariko and Drew Weissman. He is noted for developing the first fully integrated university-based academic health system in the country at the University of Pennsylvania and expanding the Medical Centers regional footprint by acquiring hospitals and private practices, including Pennsylvania Hospital and Penn Presbyterian Medical Center. Dr. Kelleys impressive repertoire of roles has included Dean of the Perelman School of Medicine, CEO of the University of Pennsylvania Medical Center, and Founding CEO of the Penn Health System (now known as Penn Medicine).

Prior appointments included Professor of Medicine, Associate Professor of Biochemistry, and Chief of Rheumatic and Genetic Diseases at Duke University, followed by Professor of Biological Chemistry and Internal Medicine, and Chair of Internal Medicine with the Medical School at the University of Michigan in Ann Arbor.

Dr. Kelley was known for his breakthrough research and leadership of academic medical programs at Duke and the University of Michigan when he arrived at Penn. During Dr. Kelleys Tenure, the Perelman School became a research powerhouse moving the school into the top 3 rankings for NIH funding. There is now a Professorship named in his honor at the Perelman School of Medicine.

Dr. Kelley earned his Doctor of Medicine at Emory University in Atlanta, GA, in 1963 and subsequently served an internship and residency in Medicine at the Parkland Memorial Hospital in Dallas, TX. He completed his senior residency in Medicine at Massachusetts General Hospital in Boston. Dr. Kelleys other titles have included Clinical Associate in Human Biochemical Genetics with the National Institutes of Health, Educator to Fellow of Medicine at Harvard University, and Macy Faculty scholar at the University of Oxford in England. Later in his career, he received an honorary Master of Arts from the University of Pennsylvania.

The President of IAOTP, Stephanie Cirami, stated, Inducting Dr. Kelley into our Hall of Fame was an effortless decision for our panel to make. In addition to his long list of accomplishments and accolades, he is well regarded and well recognized in academic medicine. We are thrilled to honor him in this way and look forward to celebrating his success with him.

Throughout his illustrious career, Dr. Kelley has received many awards, accolades and has been recognized worldwide for his outstanding leadership and commitment to the profession. He will be honored at IAOTPs 2021 Annual Awards Gala, being held at the Plaza Hotel in NYC for his selection as Top Professor of the Year in Medicine for 2020; he will be inducted on stage at the ceremony for his appointment into the Hall of Fame. In 2018 he received the Albert Nelson Marquis Lifetime Achievement Award. In 2005, Dr. Kelley was presented with the Kober Medal by the Association of American Physicians and the Emory Medal in 2000 from his alma mater, Emory University. He was the recipient of the David E. Rogers Award from the Association of American Medical Colleges, the John Phillips Award of the American College of Physicians, the Gold Medal Award from the American College of Rheumatology, the Robert H. Williams Award from the Alliance for Academic Internal Medicine, and the National Medical Research Award from the National Health Council. Dr. Kelley has been featured in many magazines and publications, including Whos Who in America, Whos Who in Medicine and Healthcare, and Whos Who in the World.

Aside from his successful career, Dr. Kelley is a sought-after lecturer, speaker, and contributor to numerous professional journals and chapters to books. He was the co-inventor of a Viral-Mediated Gene Transfer System, now the most commonly used method today for in vivo gene therapy. Dr. Kelley founded and edited numerous early editions of Kelley and Firesteins Textbook of Rheumatology and Kelleys Textbook of Internal Medicine. He was also editor-in-chief for Essentials of Internal Medicine and co-editor of Arthritis Surgery and Emerging Policies for Bio-Medical Research. Dr. Kelley has served on the Board of Directors for many public companies such as Beckman Coulter, Inc. and Merck & Co., Inc, and has been involved with many committees and subcommittees with the National Institutes of Health. He is a member of the National Academy of Medicine, The American Academy of Arts & Sciences, and the American Philosophical Society.

Looking back, Dr. Kelley attributes his success to his perseverance, his education, his mentors as well as outstanding students and trainees he has had along the way. When not working, he enjoys traveling and spending time with his family. For the future, he hopes that his contributions will continue to improve human health worldwide.

For more information on Dr. Kelley please visit: http://www.iaotp.com

Watch his video: https://www.youtube.com/watch?v=6uhxBnYVY54

About IAOTP

The International Association of Top Professionals (IAOTP) is an international boutique networking organization that handpicks the worlds finest, most prestigious top professionals from different industries. These top professionals are given an opportunity to collaborate, share their ideas, be keynote speakers, and to help influence others in their fields. This organization is not a membership that anyone can join. You have to be asked by the President or be nominated by a distinguished honorary member after a brief interview.

IAOTPs experts have given thousands of top prestigious professionals around the world, the recognition and credibility that they deserve andhave helped in building their branding empires.IAOTP prides itself to bea one of a kind boutique networking organization that hand picks only the best of the best and creates a networking platform that connects and brings these top professionals to one place.

For More information on IAOTP please visit: http://www.iaotp.com

More:
Dr. William Kelley inducted into IAOTPs Hall of Fame - PRUnderground

Read More...

Baptist Health of Northeast Florida Joins Forces with Blue Zones to Begin Building a Plan for Well-Being Transformation in Jacksonville – PR Web

Monday, February 1st, 2021

Baptist Healths vision is A Lifetime of Health, Together. That vision extends beyond the walls of our hospitals and calls us to help all people in the community live longer and healthier lives. -- Brett McClung, President and CEO of Baptist Health

MINNEAPOLIS (PRWEB) January 26, 2021

Baptist Health has invited Blue Zones to bring its expertise in well-being innovation to Jacksonville. The first phase is a Blue Zones Activate assessment and feasibility study that will help determine how to make Jacksonville a healthier and happier place to live, work, and grow old.

Research shows that where people live has a significant influence on their health even more than their genetics. Blue Zones tackles this "zip code effect" by using scientifically proven lessons of longevity, health, and happiness gleaned from their 20 years of international research to boost the well-being of entire communities.

By focusing on making permanent and semi-permanent changes to the Life Radius--the area close to home where people spend 90% of their lives--Blue Zones has helped hundreds of communities achieve measurable improvements in its residents health.

Baptist Healths vision is A Lifetime of Health, Together, said Brett McClung, President and CEO of Baptist Health. That vision extends beyond the walls of our hospitals and calls us to help all people in the community live longer and healthier lives. We are excited to build on a long legacy of community partnership by inviting Blue Zones, a proven leader in community-led health improvement, to help Jacksonville learn some new and innovative ways to achieve transformational results.

In the midst of the COVID-19 pandemic, this work begins at a time when public focus is now, more than ever, on the interconnectedness of our health to that of our friends and neighbors. As a proven and comprehensive solution influencing social determinants of health and improving health equity, the Blue Zones approach for strengthening community well-being will be critical as we navigate recovery.

In the assessment phase, which begins in January and concludes with recommendations in May, Blue Zones collaborates with local leaders to assess readiness and build a plan for change. The Blue Zones team, made up of global experts in food systems, the built environment, tobacco and alcohol use, health equity, and happiness, will work with local experts and leaders to assess the highest priority needs and opportunities, as well as strengths and challenges.

Ben Leedle, CEO of Blue Zones said, We are excited to learn from and share our knowledge with Jacksonville leaders, and we applaud Baptist Health for spearheading this movement. Improved well-being leads to healthier and happier residents, a better and more productive workforce, and a more vibrant economy. We are excited to create a transformation plan for Jacksonville that will improve the lives of current and future generations.

For more information on Blue Zones Activate or to learn how to get involved, visit bluezones.com/activate-jacksonville.

About Blue Zones Blue Zones employs evidence-based ways to help people live longer, better. The companys work is rooted in explorations and research done by National Geographic Fellow Dan Buettner in Blue Zones regions around the world, where people live extraordinarily long and/or happy lives. The original research and findings were released in Buettner's bestselling books The Blue Zones Solution, The Blue Zones of Happiness, The Blue Zones, Thrive, and Blue Zones Kitchenall published by National Geographic books. Using original Blue Zones research, Blue Zones works with cities and counties to make healthy choices easier through permanent and semi-permanent changes to our human-made surroundings. Participating communities have experienced double-digit drops in obesity and tobacco use and have saved millions of dollars in healthcare costs. For more information, visit bluezones.com.

About Baptist Health Baptist Health is a faith-based, mission-driven system in Northeast Florida comprised of Baptist Medical Center Jacksonville; Baptist Medical Center Beaches; Baptist Medical Center Nassau; Baptist Medical Center South; Baptist Clay Medical Campus and Wolfson Childrens Hospital the regions only childrens hospital. All Baptist Health hospitals, along with Baptist Home Health Care, have achieved Magnet status for excellence in patient care. Baptist Health is part of Coastal Community Health, a highly integrated regional hospital network focused on significant initiatives designed to enhance the quality and value of care provided to our contiguous communities. Baptist Health has the areas only dedicated heart hospital; orthopedic institute; womens services; neurological institute, including comprehensive neurosurgical services, a comprehensive stroke center and two primary stroke centers; a Bariatric Center of Excellence; a full range of psychology and psychiatry services; urgent care services; and primary and specialty care physicians offices throughout Northeast Florida. The Baptist MD Anderson Cancer Center is a regional destination for multidisciplinary cancer care, which is clinically integrated with the MD Anderson Cancer Center, the internationally renowned cancer treatment and research institution in Houston. For more details, visit baptistjax.com.

Share article on social media or email:

Original post:
Baptist Health of Northeast Florida Joins Forces with Blue Zones to Begin Building a Plan for Well-Being Transformation in Jacksonville - PR Web

Read More...

Dancing on Ice’s Colin Jackson to get stem cell op as he’s got ‘knees of 85-year-old’ – Mirror Online

Monday, February 1st, 2021

At the age of 53, Dancing On Ice favourite Colin Jackson looks every inch the super-fit Olympian.

But the sporting icons winning smile as he skates with partner Klabera Komini hides a world of pain.

Because today, 110m hurdles hero Colin tells how track stardom has left him with the knees of an octogenarian.

The former world record holder is in constant agony, struggles to get out of his car and fears he could even end up in a wheelchair.

But he is now facing his biggest hurdle of all stem cell therapy to repair his damaged knees.

Colin says the treatment, which will begin next week, is the last roll of the dice to avoid joint replacement surgery.

Im in constant pain but you learn to live it with it, says the 1988 Olympic silver medallist and former World Champion hurdler.

Ive got the body of a man in his mid-30s but the knees of a man in his mid-80s. Ive had seven operations on my knees already four on the right knee and three on the left knee.

"I just cant face any more.

My knees lock up after long car journeys, and getting in and out of the bath is awkward.

It takes me ages to get going in the morning.

Colins glittering career left him with extensive damage to his kneecaps, cartilage, ligaments and tendons and he also has a degenerative condition that can make it difficult to get out of bed, let alone skate.

He needs to do a string of warm-up exercises every morning and has to take paracetamol and ibuprofen before every rink training session.

But Colin, a runner-up on Strictly Come Dancing in 2005, reckons his mental toughness is getting him through his sessions on the ice.

His family tried to talk him out of appearing on the hit ITV show, fearing he could suffer life-changing injuries if he falls.

But the will to win that once shot Colin to athletics stardom shone through.

I dont believe my knees will hamper my progress on the show, he says. That may sound contradictory because I am in pain, but Im in pain every day anyway, whether Im on the show or not.

My family is worried and just keep telling me to be careful but Im just not built that way. I love the challenge.

Right now, Ill compete and worry about things afterwards.

Colin is pinning all his hopes on starting the stem cell therapy and says hes praying for a miracle.

Its definitely the last roll of the dice to avoid knee replacement surgery somewhere down the line, he says.

Otherwise I will have to have more surgery at some stage. There is no doubt about that.

Im praying for a miracle because I really dont want knee replacements and I dont want to be in a wheelchair.

I want to be able to walk down the street when Im older. As part of his treatment, the BBC athletics commentator will have one million stem cells injected into each knee and more cells delivered afterwards via an IV drip.

The first session to prepare his body for the jabs will take place at Harley Street Stem Cell Clinic in London next week. Overall, it will cost him 25,000.

Colin is being treated by Dr Aamer Khan, who has specialised in the remarkable therapy since 2009.

Dr Khan said: Human stem cells are able to develop into different cell types that can be used to replace damaged tissue all over the body. They can drastically improve an individuals overall quality of life by reducing pain.

Colins condition will get worse if untreated and joint replacement is a real possibility if the therapy doesnt work. If it does, however, Colin could feel improvements in just four weeks and the full benefit after 12.

In the meantime, he plans to keep going for as long as he possibly can on Dancing On Ice a show notorious for falls and injuries.

So far this series, two professional skaters have been hospitalised because of training injuries and celeb contestant Denise van Outen dislocated her shoulder.

But Colin knows hes no longer the young athlete who thought nothing of pushing himself to the limit during his career.

When you are young, you dont worry about it, he says.

But when you get older, you realise the grief you have caused yourself. On a good day, the pain level is three out of 10 but on a bad day its a 10.

Being down on my knees is painful and I have to be careful with twisting and turning. But I still work out, I still go to the gym and do yoga and Pilates because I dont want to give in to it.

Before I train I will take ibuprofen so I dont exacerbate the problem.

But Im worried about walking on the pavement when its icy out, so I must be completely mad to be doing Dancing On Ice!

Colin says he was aware of what was coming during his career. I knew my knees were going to be a problem but I hadnt started to feel it until I got into my 50s, he says.

I still want an outdoor life. I still want to ski and go snowboarding. Im terrified my lifestyle will be badly affected but also that the everyday things might become difficult.

Colin says that these days, he cant even contemplate the sport that made him famous.

I couldnt clear a hurdle. Forget it. My knees wont let me, he says.

Ive attempted some small hurdles but the next day, my knees were really killing me. I just cant do those things any more.

When Dr Khan told me he may be able to help just before Christmas, I said, Lets give it a go. Ive got nothing to lose.

But this is a degenerative problem and there is huge potential I could end up in a wheelchair without a knee replacement or if the stem cell therapy doesnt work.

Colin realises people will probably think he is crazy for doing Dancing On Ice when the consequences of a fall could be so serious for him.

But he says: I feel that the other parts of my body are strong.

Being an athlete, Ive had so much treatment, injections and surgeries and still competed and had to perform so I am in the same mindset for Dancing On Ice. Its not new to me.

Every day as an athlete, I would perform with injuries and then hobble into bed but then go out the next day and do it all again.

It is something built into you when you have competed at the highest level, but Im not a fool.

Im not going to be like I was at 21 after the treatment, but if I can get 10% better, thats a huge amount of pain relief.

If the therapy doesnt work and Dr Khan says, Stop going to the gym, stop skiing and snowboarding because they are going to wear out your knees, then that would be difficult.

Its on my mind because being sedentary is not a good thing for me.

Its going to be a bitter pill if it comes to that but Im just praying the stem cells work their miracle.

Continue reading here:
Dancing on Ice's Colin Jackson to get stem cell op as he's got 'knees of 85-year-old' - Mirror Online

Read More...

Canada’s blood supply has a diversity problem and people are dying because of it – CBC.ca

Monday, February 1st, 2021

Lauren Sanostill wonders,if things were different, whether her father's life couldhave been saved.

"You always wonder if there was someone in the registry who was a bettermatch would have resulted in better outcomes and less transplant complications."

Mark Sanowas a 52-year-old Toronto father of three. He worked in the financial industry as a marketing manager and in his spare time was an avid sportsman who loved tennis, hockey and especially skiing.

In November of 2019 he was diagnosed with a rare form of leukemia. The only thing that couldsave his life, doctors told his family,was a stem cell transplant;a critical treatment for blood cancers and dozens of other diseases.

According to Canadian Blood Services (CBS), stem cells are the body's basic building blocks the raw material from which all cells are made. In blood, stem cells can become red, white blood cells or even blood platelets.

"Without stem cells, the body cannot make the blood cells needed for the immune system to function," CBS says, which runs the national blood bank.

It says a patient must find a match with a donor, and that is usually a person who shares the same ethnic background.

CBS says right now, donors to Canada's blood stem cell registry are more than two-thirds Caucasian, with the other third fracturedin uneven splintersacross race and ethnicity.

It means an Asian patient like Sano, according to the Canadian Blood Services stem cell registry, would have anywhere from seven to less than one per cent chanceof finding a match, depending on hisparticular genetic background.

So when the Sano family sought a match, they found a lack of minority donors who were aclose enough. Sano's daughter Lauren was the closest they could find and even then, she was far from ideal.

"I ended up being a half-match for him and was his donor.It was the most fulfilling and grounding experience."

As fulfilling as it was, it wasn't enough.Sano died at Princess Margaret Hospital in October 2020, 18 months after he was first diagnosed.

Lauren still wonders, whether her dad's life could have been saved, had they found the right donor from a more racially diverse pool of donors.

"I feel very lucky I was able to give him the gift of life.I was at least grateful that I was able to do this for my dad."

The dearth of diversity in Canada's stem cell registry is a problem Canadian Blood Services is familiar with, according toHeidi Elmoazzen, the agency's director of stem cells. Shehas been actively working on increasing the pool of minority donors to give minority patientsa better shot at getting better.

"We find that people tend to find matches within the same ethnic or racial background as them, which is why we're trying to build a registry that reflects the unique diversity we have here in Canada."

Some groups are more diverse than others when it comes to the make up of their stem cells, according to Elmoazzen. For example, she saysBlack people tend to be the most diverse.

A Black person whose ancestors are from the Caribbean might not have the same markers as someone from say, eastern Africa, which makes finding a match challenging.

Adding to the complication is that to harvest stem cells, you literally need young blood.Only young people, between the ages of 17 and 35 can apply.

The ongoing COVID-19 pandemic has also disrupted recruitment efforts, Elmoazzen says.Canadian Blood Services finds 60 to 70 per cent of its potential stem cell donors during its community clinics and with everyone staying home, the number of people visiting is down.

"It's had a heavy impact on our ability to recruit donors this year," she adds.

Still, virtual drives are underway. People interested in donating can still sign up through the Canadian Blood Services website.

There are also volunteers like Lauren Sano, who along with a number of Western University students will be pushing for donations in a virtual blood stem cell drive this month in honour of Black History Month and in April.

The hope is that by reaching out to diverse communities, Sanosays her goal is to help people make donating blood a habit. She says she hopes that willnot only will boost the blood supply, but the supply of blood products, such as stem cells and platelets as well.

See more here:
Canada's blood supply has a diversity problem and people are dying because of it - CBC.ca

Read More...

Autologous Stem Cell and Non Stem Based therapies Market Share, Size 2021 Global Industry Future Trends, Growth, Strategies,, Segmentation, In-depth…

Monday, February 1st, 2021

Autologous Stem Cell and Non Stem Based therapies Market delivers a succinct analysis of industry size, regional growth and revenue forecasts for the upcoming years. The report further sheds light on significant challenges and the latest growth strategies adopted by manufacturers who are a part of the competitive spectrum of this business domain.

Autologous Stem Cell and Non Stem Based therapies Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027. Rise in the prevalence of Cancer and Diabetes in all age groups population. Furthermore, the growing geriatric population is another key factor which drives the Autologous Stem Cell and Non Stem Based therapies Market.

Get Sample Copy of The Report@https://brandessenceresearch.com/requestSample/PostId/61

Scope Of Market Reports

Autologous Stem Cell transplantation is a process in which cells from which all blood cells develop are removed, preserved and later given to the same person after severe treatment. In autologous stem cell transplantation, the patient itself acts as stem cell donor. These cells are collected in advance while they are in remission and returned to the patient at a later stage i.e., after two months. They are used to replace stem cells which have been impaired by high doses of chemotherapy.It is important to realize that the processes required in a stem cell transplant are lengthy and complicated. A transplant involves a lot of preparation and a lot of care after procedure. Many people have a single autologous stem cell transplant while others mainly having myeloma or tumors; have two or more continuous transplants.

The initial step in an autologous stem cell transplant is gathering the stem cells. Physicians usually collect stem cells from the bloodstream (peripheral blood stem cells) in advance. A mobilization treatment is used. When the stem cells are in the bloodstream, then collection process starts.The blood is separated using an Apheresis machine. This procedure requires a few hours, and is repeated until the appropriate amount of stem cells is collected. Once the stem cells are harvested, they are frozen in our Stem Cell Processing and Cryopreservation Laboratory until its time to transplant.

Autologous Stem Cell and Non Stem Based therapies Market is segmented on the basis of Application, product, End user and Geography. Based upon ApplicationAutologous Stem Cell and Non Stem Based therapies Market is classified as Neurodegenerative Disorders,Autoimmune Diseases, cancer &Tumors, Cardiovascular Diseases and Others. Based on the ProductAutologous Stem Cell and Non Stem Based therapies Market is classified into Blood Pressure Monitoring Devices, Pulmonary Pressure Monitoring Devices and Intracranial Pressure Monitoring Devices. On the basis of End users Autologous Stem Cell and Non Stem Based therapies Market is classified into Hospitals, Ambulatory Surgical Centers and Others.

The regions covered in Autologous Stem Cell and Non Stem Based therapies Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, Global Melanoma Drug Market sub divided in to U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Rising prevalence of cancer and diabetes among people across all age groups, growing geriatric population, increasing demand for autologous stem cell and non-stem cell based therapies is another factor, which is likely to create a heightened demand. Moreover, Favorable reimbursement policies across several nations are also boosting market. Risks and complications associated with the Autologous Stem Cell and Non Stem Based therapy such as diarrhea, hair loss, nausea, severe infections, vomiting, heart complications, and infertility and thehigh cost of autologous cellular therapies ranging from $500,000 to $1,000,000 restraint the market. Innovation of some newtherapies with improved efficacy, fewer side effects are expected to offer good opportunity for growth of Autologous Stem Cell and Non Stem Based therapies Market in the future.

Get Methodology of Report @https://brandessenceresearch.com/requestMethodology/PostId/61

North America is probable to attain the largest share of the Autologous Stem Cell and Non Stem Based therapies Market in terms of revenue and expected to hold the position followed by Europe region. This is due to less risk related with the treatment. Also, the demand for these treatments is high due to their ability to cure a significant number of infectious diseases. Autologous stem cell and non-stem cell based therapies do not require an outside donor hence the treatment is less infectious and cheap. However, Asia Pacific is expected to show the high growth in the forecast period. The demand in this region will be led by countries such as China, India, Malaysia, and Vietnam. The demand is likely to grow as autologous stem cell and non-stem cell based therapies aid in the efficient management of cardiovascular diseases as well. Rising healthcare facilities as well as increasing tax and reimbursement procedures is also estimated to help in the growth of the autologous stem cell and non-stem cell based therapies market in the Asia Pacific.

Furthermore, increase in awareness of disease and government initiatives for improving health care facilities are expected to boost the regional market to a certain extent.

By Application Analysis Neurodegenerative Disorders, Autoimmune Diseases, Cancer & Tumors, Cardiovascular Diseases, Others

By Product Analysis Blood Pressure Monitoring Devices, Pulmonary Pressure Monitoring Devices, Intracranial Pressure Monitoring Devices, Others

By End User Analysis Hospitals, Ambulatory Surgical centers, Others

North America, US, Mexico, Chily, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, South Korea, Japan, India, Southeast Asia, Latin America, Brazil, The Middle East and Africa, GCC, Africa, Rest of Middle East and Africa

Get Full Report :@https://brandessenceresearch.com/chemical-materials/autologous-stem-cell-therapies-market

Related Report @https://www.prnewswire.com/news-releases/at-19-71cagr-zero-trust-security-market-size-is-projected-to-reach-94-35-billion-by-2027says-brandessence-market-research-301213906.html

https://www.marketwatch.com/press-release/at-1971-cagr-zero-trust-security-market-size-is-projected-to-reach-9435-billion-by-2027-says-brandessence-market-research-2021-01-25?tesla=y

https://www.marketwatch.com/press-release/at-cagr-of-1222-remote-patient-monitoring-market-size-is-expected-to-reach-usd-293638-million-by-2025-says-brandessence-market-research-2021-01-12?tesla=y

About Us:

Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact us at: +44-2038074155 or mail us atsales@industrystatsreport.com

Website:https://brandessenceresearch.com/

Article:https://businessstatsnews.com

Blog:http://www.dailyindustrywatch.com

Blog:https://marketsize.biz

Blog:https://technologyindustrynews.com

Blog:https://marketstatsreport.com

Here is the original post:
Autologous Stem Cell and Non Stem Based therapies Market Share, Size 2021 Global Industry Future Trends, Growth, Strategies,, Segmentation, In-depth...

Read More...

Merck Receives Positive EU CHMP Opinion for Expanded Approval of KEYTRUDA (pembrolizumab) in Certain Patients With Relapsed or Refractory Classical…

Monday, February 1st, 2021

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of an expanded label for KEYTRUDA, Mercks anti-PD-1 therapy. The opinion is recommending KEYTRUDA as monotherapy for the treatment of adult and pediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.

This recommendation is based on results from the pivotal Phase 3 KEYNOTE-204 trial, in which KEYTRUDA monotherapy demonstrated a significant improvement in progression-free survival (PFS) compared with brentuximab vedotin (BV), a commonly used treatment. KEYTRUDA reduced the risk of disease progression or death by 35% (HR=0.65 [95% CI, 0.48-0.88]; p=0.00271) and showed a median PFS of 13.2 months versus 8.3 months for patients treated with BV. The recommendation is also based on supportive data from an updated analysis of the KEYNOTE-087 trial, which supported the European Commissions (EC) approval of KEYTRUDA for the treatment of adult patients with relapsed or refractory cHL who have failed ASCT and BV or who are transplant ineligible and have failed BV. The CHMPs recommendation will now be reviewed by the EC for marketing authorization in the European Union (EU), and a final decision is expected in the first quarter of 2021. If approved, this will be the first pediatric indication for KEYTRUDA in the EU.

This positive opinion reinforces the importance of KEYTRUDA for certain adult and pediatric patients with relapsed or refractory classical Hodgkin lymphoma in the European Union, said Dr. Vicki Goodman, vice president, clinical research, Merck Research Laboratories. We look forward to the decision by the European Commission and will continue to expand our clinical development program in blood cancers with KEYTRUDA and our recently acquired investigational therapies to help address the unmet needs of patients.

Merck is studying KEYTRUDA across hematologic malignancies through a broad clinical program, including multiple registrational trials in cHL and primary mediastinal large B-cell lymphoma and more than 60 investigator-initiated studies across 15 tumors. In addition to KEYTRUDA, Merck is evaluating two clinical-stage assets for the treatment of patients with hematologic malignancies: MK-1026 (formerly ARQ 531), a Brutons tyrosine kinase inhibitor, and VLS-101, an antibody-drug conjugate targeting ROR1.

About KEYNOTE-204

KEYNOTE-204 (ClinicalTrials.gov, NCT02684292) is a randomized, open-label, Phase 3 trial evaluating KEYTRUDA monotherapy compared with BV for the treatment of patients with relapsed or refractory cHL. The primary endpoints are PFS and overall survival (OS), and the secondary endpoints include objective response rate (ORR), complete remission rate (CRR) and safety. The study enrolled 304 patients, aged 18 years and older, who were randomized to receive either:

About Hodgkin Lymphoma

Hodgkin lymphoma is a type of lymphoma that develops in the white blood cells called lymphocytes, which are part of the immune system. Hodgkin lymphoma can start almost anywhere most often in lymph nodes in the upper part of the body, with the most common sites being in the chest, neck or under the arms. Worldwide, there were approximately 83,000 new cases of Hodgkin lymphoma diagnosed, and more than 23,000 people died from the disease in 2020. In the EU, there were nearly 20,000 new cases of Hodgkin lymphoma diagnosed, and nearly 4,000 people died from the disease in 2020. Classical Hodgkin lymphoma accounts for more than nine in 10 cases of Hodgkin lymphoma in developed countries.

About KEYTRUDA (pembrolizumab) Injection, 100 mg

KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of the bodys immune system to help detect and fight tumor cells. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.

Merck has the industrys largest immuno-oncology clinical research program. There are currently more than 1,300 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient's likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers.

Selected KEYTRUDA (pembrolizumab) Indications in the U.S.

Melanoma

KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma.

KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.

Non-Small Cell Lung Cancer

KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.

KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.

KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with NSCLC expressing PD-L1 [tumor proportion score (TPS) 1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic.

KEYTRUDA, as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS 1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.

Small Cell Lung Cancer

KEYTRUDA is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least 1 other prior line of therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Head and Neck Squamous Cell Cancer

KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).

KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [combined positive score (CPS) 1] as determined by an FDA-approved test.

KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.

Classical Hodgkin Lymphoma

KEYTRUDA is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL).

KEYTRUDA is indicated for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy.

Primary Mediastinal Large B-Cell Lymphoma

KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy. KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy.

Urothelial Carcinoma

KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 (CPS 10), as determined by an FDA-approved test, or in patients who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

KEYTRUDA is indicated for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

Microsatellite Instability-High or Mismatch Repair Deficient Cancer

KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The safety and effectiveness of KEYTRUDA in pediatric patients with MSI-H central nervous system cancers have not been established.

Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer

KEYTRUDA is indicated for the first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC).

Gastric Cancer

KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS 1) as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Esophageal Cancer

KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (CPS 10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.

Cervical Cancer

KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS 1) as determined by an FDA-approved test. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Hepatocellular Carcinoma

KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Merkel Cell Carcinoma

KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Renal Cell Carcinoma

KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

Tumor Mutational Burden-High

KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [10 mutations/megabase] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established.

Cutaneous Squamous Cell Carcinoma

KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.

Triple-Negative Breast Cancer

KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS 10) as determined by an FDA-approved test. This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Selected Important Safety Information for KEYTRUDA

Severe and Fatal Immune-Mediated Adverse Reactions

KEYTRUDA is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death receptor-1 (PD-1) or the programmed death ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions. Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, can affect more than one body system simultaneously, and can occur at any time after starting treatment or after discontinuation of treatment. Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.

Monitor patients closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions. Early identification and management are essential to ensure safe use of antiPD-1/PD-L1 treatments. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.

Withhold or permanently discontinue KEYTRUDA depending on severity of the immune-mediated adverse reaction. In general, if KEYTRUDA requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose adverse reactions are not controlled with corticosteroid therapy.

Immune-Mediated Pneumonitis

KEYTRUDA can cause immune-mediated pneumonitis. The incidence is higher in patients who have received prior thoracic radiation. Immune-mediated pneumonitis occurred in 3.4% (94/2799) of patients receiving KEYTRUDA, including fatal (0.1%), Grade 4 (0.3%), Grade 3 (0.9%), and Grade 2 (1.3%) reactions. Systemic corticosteroids were required in 67% (63/94) of patients. Pneumonitis led to permanent discontinuation of KEYTRUDA in 1.3% (36) and withholding in 0.9% (26) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, 23% had recurrence. Pneumonitis resolved in 59% of the 94 patients.

Pneumonitis occurred in 8% (31/389) of adult patients with cHL receiving KEYTRUDA as a single agent, including Grades 3-4 in 2.3% of patients. Patients received high-dose corticosteroids for a median duration of 10 days (range: 2 days to 53 months). Pneumonitis rates were similar in patients with and without prior thoracic radiation. Pneumonitis led to discontinuation of KEYTRUDA in 5.4% (21) of patients. Of the patients who developed pneumonitis, 42% of these patients interrupted KEYTRUDA, 68% discontinued KEYTRUDA, and 77% had resolution.

Immune-Mediated Colitis

KEYTRUDA can cause immune-mediated colitis, which may present with diarrhea. Cytomegalovirus infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies. Immune-mediated colitis occurred in 1.7% (48/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (1.1%), and Grade 2 (0.4%) reactions. Systemic corticosteroids were required in 69% (33/48); additional immunosuppressant therapy was required in 4.2% of patients. Colitis led to permanent discontinuation of KEYTRUDA in 0.5% (15) and withholding in 0.5% (13) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, 23% had recurrence. Colitis resolved in 85% of the 48 patients.

Hepatotoxicity and Immune-Mediated Hepatitis

KEYTRUDA as a Single Agent

KEYTRUDA can cause immune-mediated hepatitis. Immune-mediated hepatitis occurred in 0.7% (19/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (0.4%), and Grade 2 (0.1%) reactions. Systemic corticosteroids were required in 68% (13/19) of patients; additional immunosuppressant therapy was required in 11% of patients. Hepatitis led to permanent discontinuation of KEYTRUDA in 0.2% (6) and withholding in 0.3% (9) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, none had recurrence. Hepatitis resolved in 79% of the 19 patients.

KEYTRUDA with Axitinib

KEYTRUDA in combination with axitinib can cause hepatic toxicity. Monitor liver enzymes before initiation of and periodically throughout treatment. Consider monitoring more frequently as compared to when the drugs are administered as single agents. For elevated liver enzymes, interrupt KEYTRUDA and axitinib, and consider administering corticosteroids as needed. With the combination of KEYTRUDA and axitinib, Grades 3 and 4 increased alanine aminotransferase (ALT) (20%) and increased aspartate aminotransferase (AST) (13%) were seen, which was at a higher frequency compared to KEYTRUDA alone. Fifty-nine percent of the patients with increased ALT received systemic corticosteroids. In patients with ALT 3 times upper limit of normal (ULN) (Grades 2-4, n=116), ALT resolved to Grades 0-1 in 94%. Among the 92 patients who were rechallenged with either KEYTRUDA (n=3) or axitinib (n=34) administered as a single agent or with both (n=55), recurrence of ALT 3 times ULN was observed in 1 patient receiving KEYTRUDA, 16 patients receiving axitinib, and 24 patients receiving both. All patients with a recurrence of ALT 3 ULN subsequently recovered from the event.

Immune-Mediated Endocrinopathies

Adrenal Insufficiency

KEYTRUDA can cause primary or secondary adrenal insufficiency. For Grade 2 or higher, initiate symptomatic treatment, including hormone replacement as clinically indicated. Withhold KEYTRUDA depending on severity. Adrenal insufficiency occurred in 0.8% (22/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (0.3%), and Grade 2 (0.3%) reactions. Systemic corticosteroids were required in 77% (17/22) of patients; of these, the majority remained on systemic corticosteroids. Adrenal insufficiency led to permanent discontinuation of KEYTRUDA in <0.1% (1) and withholding in 0.3% (8) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement.

Hypophysitis

KEYTRUDA can cause immune-mediated hypophysitis. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field defects. Hypophysitis can cause hypopituitarism. Initiate hormone replacement as indicated. Withhold or permanently discontinue KEYTRUDA depending on severity. Hypophysitis occurred in 0.6% (17/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (0.3%), and Grade 2 (0.2%) reactions. Systemic corticosteroids were required in 94% (16/17) of patients; of these, the majority remained on systemic corticosteroids. Hypophysitis led to permanent discontinuation of KEYTRUDA in 0.1% (4) and withholding in 0.3% (7) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement.

Thyroid Disorders

KEYTRUDA can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement for hypothyroidism or institute medical management of hyperthyroidism as clinically indicated. Withhold or permanently discontinue KEYTRUDA depending on severity. Thyroiditis occurred in 0.6% (16/2799) of patients receiving KEYTRUDA, including Grade 2 (0.3%). None discontinued, but KEYTRUDA was withheld in <0.1% (1) of patients.

Hyperthyroidism occurred in 3.4% (96/2799) of patients receiving KEYTRUDA, including Grade 3 (0.1%) and Grade 2 (0.8%). It led to permanent discontinuation of KEYTRUDA in <0.1% (2) and withholding in 0.3% (7) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement. Hypothyroidism occurred in 8% (237/2799) of patients receiving KEYTRUDA, including Grade 3 (0.1%) and Grade 2 (6.2%). It led to permanent discontinuation of KEYTRUDA in <0.1% (1) and withholding in 0.5% (14) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement. The majority of patients with hypothyroidism required long-term thyroid hormone replacement. The incidence of new or worsening hypothyroidism was higher in 1185 patients with HNSCC, occurring in 16% of patients receiving KEYTRUDA as a single agent or in combination with platinum and FU, including Grade 3 (0.3%) hypothyroidism. The incidence of new or worsening hypothyroidism was higher in 389 adult patients with cHL (17%) receiving KEYTRUDA as a single agent, including Grade 1 (6.2%) and Grade 2 (10.8%) hypothyroidism.

Type 1 Diabetes Mellitus (DM), Which Can Present With Diabetic Ketoacidosis

Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated. Withhold KEYTRUDA depending on severity. Type 1 DM occurred in 0.2% (6/2799) of patients receiving KEYTRUDA. It led to permanent discontinuation in <0.1% (1) and withholding of KEYTRUDA in <0.1% (1). All patients who were withheld reinitiated KEYTRUDA after symptom improvement.

Immune-Mediated Nephritis With Renal Dysfunction

KEYTRUDA can cause immune-mediated nephritis. Immune-mediated nephritis occurred in 0.3% (9/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (0.1%), and Grade 2 (0.1%) reactions. Systemic corticosteroids were required in 89% (8/9) of patients. Nephritis led to permanent discontinuation of KEYTRUDA in 0.1% (3) and withholding in 0.1% (3) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, none had recurrence. Nephritis resolved in 56% of the 9 patients.

Immune-Mediated Dermatologic Adverse Reactions

KEYTRUDA can cause immune-mediated rash or dermatitis. Exfoliative dermatitis, including Stevens-Johnson syndrome, drug rash with eosinophilia and systemic symptoms, and toxic epidermal necrolysis, has occurred with antiPD-1/PD-L1 treatments. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate nonexfoliative rashes. Withhold or permanently discontinue KEYTRUDA depending on severity. Immune-mediated dermatologic adverse reactions occurred in 1.4% (38/2799) of patients receiving KEYTRUDA, including Grade 3 (1%) and Grade 2 (0.1%) reactions. Systemic corticosteroids were required in 40% (15/38) of patients. These reactions led to permanent discontinuation in 0.1% (2) and withholding of KEYTRUDA in 0.6% (16) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, 6% had recurrence. The reactions resolved in 79% of the 38 patients.

Other Immune-Mediated Adverse Reactions

The following clinically significant immune-mediated adverse reactions occurred at an incidence of <1% (unless otherwise noted) in patients who received KEYTRUDA or were reported with the use of other antiPD-1/PD-L1 treatments. Severe or fatal cases have been reported for some of these adverse reactions. Cardiac/Vascular: Myocarditis, pericarditis, vasculitis; Nervous System: Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barr syndrome, nerve paresis, autoimmune neuropathy; Ocular: Uveitis, iritis and other ocular inflammatory toxicities can occur. Some cases can be associated with retinal detachment. Various grades of visual impairment, including blindness, can occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, as this may require treatment with systemic steroids to reduce the risk of permanent vision loss; Gastrointestinal: Pancreatitis, to include increases in serum amylase and lipase levels, gastritis, duodenitis; Musculoskeletal and Connective Tissue: Myositis/polymyositis rhabdomyolysis (and associated sequelae, including renal failure), arthritis (1.5%), polymyalgia rheumatica; Endocrine: Hypoparathyroidism; Hematologic/Immune: Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection.

Infusion-Related Reactions

KEYTRUDA can cause severe or life-threatening infusion-related reactions, including hypersensitivity and anaphylaxis, which have been reported in 0.2% of 2799 patients receiving KEYTRUDA. Monitor for signs and symptoms of infusion-related reactions. Interrupt or slow the rate of infusion for Grade 1 or Grade 2 reactions. For Grade 3 or Grade 4 reactions, stop infusion and permanently discontinue KEYTRUDA.

Complications of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Fatal and other serious complications can occur in patients who receive allogeneic HSCT before or after antiPD-1/PD-L1 treatment. Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute and chronic GVHD, hepatic veno-occlusive disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between antiPD-1/PD-L1 treatment and allogeneic HSCT. Follow patients closely for evidence of these complications and intervene promptly. Consider the benefit vs risks of using antiPD-1/PD-L1 treatments prior to or after an allogeneic HSCT.

Increased Mortality in Patients With Multiple Myeloma

In trials in patients with multiple myeloma, the addition of KEYTRUDA to a thalidomide analogue plus dexamethasone resulted in increased mortality. Treatment of these patients with an antiPD-1/PD-L1 treatment in this combination is not recommended outside of controlled trials.

Embryofetal Toxicity

Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman. Advise women of this potential risk. In females of reproductive potential, verify pregnancy status prior to initiating KEYTRUDA and advise them to use effective contraception during treatment and for 4 months after the last dose.

Adverse Reactions

In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9% of 555 patients with advanced melanoma; adverse reactions leading to permanent discontinuation in more than one patient were colitis (1.4%), autoimmune hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and cardiac failure (0.4%). The most common adverse reactions (20%) with KEYTRUDA were fatigue (28%), diarrhea (26%), rash (24%), and nausea (21%).

In KEYNOTE-054, KEYTRUDA was permanently discontinued due to adverse reactions in 14% of 509 patients; the most common (1%) were pneumonitis (1.4%), colitis (1.2%), and diarrhea (1%). Serious adverse reactions occurred in 25% of patients receiving KEYTRUDA. The most common adverse reaction (20%) with KEYTRUDA was diarrhea (28%).

Here is the original post:
Merck Receives Positive EU CHMP Opinion for Expanded Approval of KEYTRUDA (pembrolizumab) in Certain Patients With Relapsed or Refractory Classical...

Read More...

Merck Presents Results From Head-to-Head Phase 3 KEYNOTE-598 Trial Evaluating KEYTRUDA (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA…

Monday, February 1st, 2021

In KEYNOTE-598, the addition of ipilimumab to KEYTRUDA did not improve overall survival or progression-free survival, and patients who received the combination were more likely to experience serious side effects than those who received KEYTRUDA monotherapy, said Dr. Michael Boyer, chief clinical officer and conjoint chair of thoracic oncology, Chris OBrien Lifehouse, Camperdown, NSW, Australia. KEYTRUDA monotherapy remains a standard of care for the first-line treatment of certain patients with metastatic non-small cell lung cancer whose tumors express PD-L1.

As a leader in lung cancer, we are pursuing a broad clinical program to better understand the potential of KEYTRUDA-based combinations to improve survival outcomes for patients with this devastating disease, said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. KEYNOTE-598 is the first head-to-head study designed to answer the question of whether combining KEYTRUDA with ipilimumab provided additional clinical benefits beyond treatment with KEYTRUDA alone in certain patients with metastatic non-small cell lung cancer. The results are clear the combination did not add clinical benefit but did add toxicity.

These results were presented in the Presidential Symposium at the IASLC 2020 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer on Friday, Jan. 29 and published in the Journal of Clinical Oncology. As previously announced in Nov. 2020, the study was discontinued due to futility based on the recommendation of an independent Data Monitoring Committee (DMC), which determined the benefit/risk profile of KEYTRUDA in combination with ipilimumab did not support continuing the trial. The DMC also advised that patients in the study discontinue treatment with ipilimumab/placebo.

KEYNOTE-598 Study Design and Additional Data (Late-Breaking Abstract #PS01.09)

KEYNOTE-598 (ClinicalTrials.gov, NCT03302234) is a randomized, double-blind, Phase 3 trial designed to evaluate KEYTRUDA in combination with ipilimumab compared to KEYTRUDA monotherapy as first-line treatment for patients with metastatic NSCLC without EGFR or ALK genomic tumor aberrations and whose tumors express PD-L1 (TPS 50%). The dual primary endpoints are OS and PFS. Secondary endpoints include objective response rate (ORR), duration of response (DOR) and safety.

The study enrolled 568 patients who were randomized 1:1 to receive KEYTRUDA (200 mg intravenously [IV] on Day 1 of each three-week cycle for up to 35 cycles) in combination with ipilimumab (1 mg/kg IV on Day 1 of each six-week cycle for up to 18 cycles); or KEYTRUDA (200 mg IV on Day 1 of each three-week cycle for up to 35 cycles) as monotherapy. Non-binding futility criteria for the study were based on restricted mean survival time (RMST), an alternative outcome measure estimated as the area under the survival curve through a fixed timepoint. The pre-specified criteria were differences in RMST for KEYTRUDA in combination with ipilimumab and KEYTRUDA monotherapy of 0.2 at the maximum observation time and 0.1 at 24 months of follow-up.

As of data cut-off, the median study follow-up was 20.6 months. Findings showed the median OS was 21.4 months for patients randomized to KEYTRUDA in combination with ipilimumab (n=284) versus 21.9 months for those randomized to KEYTRUDA monotherapy (n=284) (HR=1.08 [95% CI, 0.85-1.37]; p=0.74). The differences in RMST for KEYTRUDA in combination with ipilimumab and KEYTRUDA monotherapy were -0.56 at the maximum observation time and -0.52 at 24 months, meeting the futility criteria for the trial and confirming the benefit/risk profile of the combination did not support continuing the study. Additionally, the median PFS was 8.2 months for patients randomized to KEYTRUDA in combination with ipilimumab versus 8.4 months for those randomized to KEYTRUDA monotherapy (HR=1.06 [95% CI, 0.86-1.30]; p=0.72). In both arms of the study, ORR was 45.4%; the median DOR was 16.1 months for patients randomized to KEYTRUDA in combination with ipilimumab versus 17.3 months for those randomized to KEYTRUDA monotherapy.

No new safety signals for KEYTRUDA monotherapy were observed. Treatment-related adverse events (TRAEs) occurred in 76.2% of patients treated with KEYTRUDA in combination with ipilimumab versus 68.3% of patients treated with KEYTRUDA monotherapy. Of these TRAEs, 35.1% vs. 19.6% were Grade 3-5, 27.7% vs. 13.9% were serious, 6.0% vs. 3.2% led to discontinuation of ipilimumab or placebo, 19.1% vs. 7.5% led to discontinuation of both drugs and 2.5% vs. 0.0% (no patients) led to death. Additionally, immune-mediated adverse events (AEs) and infusion reactions occurred in 44.7% of patients treated with KEYTRUDA in combination with ipilimumab versus 32.4% of patients treated with KEYTRUDA monotherapy. Of these immune-mediated AEs, 20.2% vs. 7.8% were Grade 3-5, 19.1% vs. 7.1% were serious, 1.8% vs. 1.1% led to discontinuation of ipilimumab or placebo, 12.1% vs. 4.3% led to discontinuation of both drugs and 2.1% vs. 0.0% (no patients) led to death.

About Lung Cancer

Lung cancer, which forms in the tissues of the lungs, usually within cells lining the air passages, is the leading cause of cancer death worldwide. Each year, more people die of lung cancer than die of colon and breast cancers combined. The two main types of lung cancer are non-small cell and small cell. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all cases. Small cell lung cancer (SCLC) accounts for about 10% to 15% of all lung cancers. Before 2014, the five-year survival rate for patients diagnosed in the U.S. with NSCLC and SCLC was estimated to be 5% and 6%, respectively.

About KEYTRUDA (pembrolizumab) Injection, 100 mg

KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of the bodys immune system to help detect and fight tumor cells. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.

Merck has the industrys largest immuno-oncology clinical research program. There are currently more than 1,300 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient's likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers.

Selected KEYTRUDA (pembrolizumab) Indications in the U.S.

Melanoma

KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma.

KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.

Non-Small Cell Lung Cancer

KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.

KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.

KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with NSCLC expressing PD-L1 [tumor proportion score (TPS) 1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic.

KEYTRUDA, as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS 1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.

Small Cell Lung Cancer

KEYTRUDA is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least 1 other prior line of therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Head and Neck Squamous Cell Cancer

KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).

KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [combined positive score (CPS) 1] as determined by an FDA-approved test.

KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.

Classical Hodgkin Lymphoma

KEYTRUDA is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL).

KEYTRUDA is indicated for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy.

Primary Mediastinal Large B-Cell Lymphoma

KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy. KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy.

Urothelial Carcinoma

KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 (CPS 10), as determined by an FDA-approved test, or in patients who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

KEYTRUDA is indicated for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

Microsatellite Instability-High or Mismatch Repair Deficient Cancer

KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The safety and effectiveness of KEYTRUDA in pediatric patients with MSI-H central nervous system cancers have not been established.

Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer

KEYTRUDA is indicated for the first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC).

Gastric Cancer

KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS 1) as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Esophageal Cancer

KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (CPS 10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.

Cervical Cancer

KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS 1) as determined by an FDA-approved test. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Hepatocellular Carcinoma

KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Merkel Cell Carcinoma

KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Renal Cell Carcinoma

KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

Tumor Mutational Burden-High

KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [10 mutations/megabase] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established.

Cutaneous Squamous Cell Carcinoma

KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.

Triple-Negative Breast Cancer

KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS 10) as determined by an FDA-approved test.

This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Selected Important Safety Information for KEYTRUDA

Severe and Fatal Immune-Mediated Adverse Reactions

KEYTRUDA is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death receptor-1 (PD-1) or the programmed death ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions. Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, can affect more than one body system simultaneously, and can occur at any time after starting treatment or after discontinuation of treatment. Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.

Monitor patients closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions. Early identification and management are essential to ensure safe use of antiPD-1/PD-L1 treatments. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.

Withhold or permanently discontinue KEYTRUDA depending on severity of the immune-mediated adverse reaction. In general, if KEYTRUDA requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose adverse reactions are not controlled with corticosteroid therapy.

Immune-Mediated Pneumonitis

KEYTRUDA can cause immune-mediated pneumonitis. The incidence is higher in patients who have received prior thoracic radiation. Immune-mediated pneumonitis occurred in 3.4% (94/2799) of patients receiving KEYTRUDA, including fatal (0.1%), Grade 4 (0.3%), Grade 3 (0.9%), and Grade 2 (1.3%) reactions. Systemic corticosteroids were required in 67% (63/94) of patients. Pneumonitis led to permanent discontinuation of KEYTRUDA in 1.3% (36) and withholding in 0.9% (26) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, 23% had recurrence. Pneumonitis resolved in 59% of the 94 patients.

Pneumonitis occurred in 8% (31/389) of adult patients with cHL receiving KEYTRUDA as a single agent, including Grades 3-4 in 2.3% of patients. Patients received high-dose corticosteroids for a median duration of 10 days (range: 2 days to 53 months). Pneumonitis rates were similar in patients with and without prior thoracic radiation. Pneumonitis led to discontinuation of KEYTRUDA in 5.4% (21) of patients. Of the patients who developed pneumonitis, 42% interrupted KEYTRUDA, 68% discontinued KEYTRUDA, and 77% had resolution.

Immune-Mediated Colitis

KEYTRUDA can cause immune-mediated colitis, which may present with diarrhea. Cytomegalovirus infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies. Immune-mediated colitis occurred in 1.7% (48/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (1.1%), and Grade 2 (0.4%) reactions. Systemic corticosteroids were required in 69% (33/48); additional immunosuppressant therapy was required in 4.2% of patients. Colitis led to permanent discontinuation of KEYTRUDA in 0.5% (15) and withholding in 0.5% (13) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, 23% had recurrence. Colitis resolved in 85% of the 48 patients.

Hepatotoxicity and Immune-Mediated Hepatitis

KEYTRUDA as a Single Agent

KEYTRUDA can cause immune-mediated hepatitis. Immune-mediated hepatitis occurred in 0.7% (19/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (0.4%), and Grade 2 (0.1%) reactions. Systemic corticosteroids were required in 68% (13/19) of patients; additional immunosuppressant therapy was required in 11% of patients. Hepatitis led to permanent discontinuation of KEYTRUDA in 0.2% (6) and withholding in 0.3% (9) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, none had recurrence. Hepatitis resolved in 79% of the 19 patients.

KEYTRUDA with Axitinib

KEYTRUDA in combination with axitinib can cause hepatic toxicity. Monitor liver enzymes before initiation of and periodically throughout treatment. Consider monitoring more frequently as compared to when the drugs are administered as single agents. For elevated liver enzymes, interrupt KEYTRUDA and axitinib, and consider administering corticosteroids as needed. With the combination of KEYTRUDA and axitinib, Grades 3 and 4 increased alanine aminotransferase (ALT) (20%) and increased aspartate aminotransferase (AST) (13%) were seen at a higher frequency compared to KEYTRUDA alone. Fifty-nine percent of the patients with increased ALT received systemic corticosteroids. In patients with ALT 3 times upper limit of normal (ULN) (Grades 2-4, n=116), ALT resolved to Grades 0-1 in 94%. Among the 92 patients who were rechallenged with either KEYTRUDA (n=3) or axitinib (n=34) administered as a single agent or with both (n=55), recurrence of ALT 3 times ULN was observed in 1 patient receiving KEYTRUDA, 16 patients receiving axitinib, and 24 patients receiving both. All patients with a recurrence of ALT 3 ULN subsequently recovered from the event.

Immune-Mediated Endocrinopathies

Adrenal Insufficiency

KEYTRUDA can cause primary or secondary adrenal insufficiency. For Grade 2 or higher, initiate symptomatic treatment, including hormone replacement as clinically indicated. Withhold KEYTRUDA depending on severity. Adrenal insufficiency occurred in 0.8% (22/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (0.3%), and Grade 2 (0.3%) reactions. Systemic corticosteroids were required in 77% (17/22) of patients; of these, the majority remained on systemic corticosteroids. Adrenal insufficiency led to permanent discontinuation of KEYTRUDA in <0.1% (1) and withholding in 0.3% (8) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement.

Hypophysitis

KEYTRUDA can cause immune-mediated hypophysitis. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field defects. Hypophysitis can cause hypopituitarism. Initiate hormone replacement as indicated. Withhold or permanently discontinue KEYTRUDA depending on severity. Hypophysitis occurred in 0.6% (17/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (0.3%), and Grade 2 (0.2%) reactions. Systemic corticosteroids were required in 94% (16/17) of patients; of these, the majority remained on systemic corticosteroids. Hypophysitis led to permanent discontinuation of KEYTRUDA in 0.1% (4) and withholding in 0.3% (7) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement.

Thyroid Disorders

KEYTRUDA can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement for hypothyroidism or institute medical management of hyperthyroidism as clinically indicated. Withhold or permanently discontinue KEYTRUDA depending on severity. Thyroiditis occurred in 0.6% (16/2799) of patients receiving KEYTRUDA, including Grade 2 (0.3%). None discontinued, but KEYTRUDA was withheld in <0.1% (1) of patients.

Hyperthyroidism occurred in 3.4% (96/2799) of patients receiving KEYTRUDA, including Grade 3 (0.1%) and Grade 2 (0.8%). It led to permanent discontinuation of KEYTRUDA in <0.1% (2) and withholding in 0.3% (7) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement. Hypothyroidism occurred in 8% (237/2799) of patients receiving KEYTRUDA, including Grade 3 (0.1%) and Grade 2 (6.2%). It led to permanent discontinuation of KEYTRUDA in <0.1% (1) and withholding in 0.5% (14) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement. The majority of patients with hypothyroidism required long-term thyroid hormone replacement. The incidence of new or worsening hypothyroidism was higher in 1185 patients with HNSCC, occurring in 16% of patients receiving KEYTRUDA as a single agent or in combination with platinum and FU, including Grade 3 (0.3%) hypothyroidism. The incidence of new or worsening hypothyroidism was higher in 389 adult patients with cHL (17%) receiving KEYTRUDA as a single agent, including Grade 1 (6.2%) and Grade 2 (10.8%) hypothyroidism.

Type 1 Diabetes Mellitus (DM), Which Can Present With Diabetic Ketoacidosis

Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated. Withhold KEYTRUDA depending on severity. Type 1 DM occurred in 0.2% (6/2799) of patients receiving KEYTRUDA. It led to permanent discontinuation in <0.1% (1) and withholding of KEYTRUDA in <0.1% (1). All patients who were withheld reinitiated KEYTRUDA after symptom improvement.

Immune-Mediated Nephritis With Renal Dysfunction

KEYTRUDA can cause immune-mediated nephritis. Immune-mediated nephritis occurred in 0.3% (9/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (0.1%), and Grade 2 (0.1%) reactions. Systemic corticosteroids were required in 89% (8/9) of patients. Nephritis led to permanent discontinuation of KEYTRUDA in 0.1% (3) and withholding in 0.1% (3) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, none had recurrence. Nephritis resolved in 56% of the 9 patients.

Immune-Mediated Dermatologic Adverse Reactions

KEYTRUDA can cause immune-mediated rash or dermatitis. Exfoliative dermatitis, including Stevens-Johnson syndrome, drug rash with eosinophilia and systemic symptoms, and toxic epidermal necrolysis, has occurred with antiPD-1/PD-L1 treatments. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate nonexfoliative rashes. Withhold or permanently discontinue KEYTRUDA depending on severity. Immune-mediated dermatologic adverse reactions occurred in 1.4% (38/2799) of patients receiving KEYTRUDA, including Grade 3 (1%) and Grade 2 (0.1%) reactions. Systemic corticosteroids were required in 40% (15/38) of patients. These reactions led to permanent discontinuation in 0.1% (2) and withholding of KEYTRUDA in 0.6% (16) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, 6% had recurrence. The reactions resolved in 79% of the 38 patients.

Other Immune-Mediated Adverse Reactions

The following clinically significant immune-mediated adverse reactions occurred at an incidence of <1% (unless otherwise noted) in patients who received KEYTRUDA or were reported with the use of other antiPD-1/PD-L1 treatments. Severe or fatal cases have been reported for some of these adverse reactions. Cardiac/Vascular: Myocarditis, pericarditis, vasculitis; Nervous System: Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barr syndrome, nerve paresis, autoimmune neuropathy; Ocular: Uveitis, iritis and other ocular inflammatory toxicities can occur. Some cases can be associated with retinal detachment. Various grades of visual impairment, including blindness, can occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, as this may require treatment with systemic steroids to reduce the risk of permanent vision loss; Gastrointestinal: Pancreatitis, to include increases in serum amylase and lipase levels, gastritis, duodenitis; Musculoskeletal and Connective Tissue: Myositis/polymyositis rhabdomyolysis (and associated sequelae, including renal failure), arthritis (1.5%), polymyalgia rheumatica; Endocrine: Hypoparathyroidism; Hematologic/Immune: Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection.

Infusion-Related Reactions

KEYTRUDA can cause severe or life-threatening infusion-related reactions, including hypersensitivity and anaphylaxis, which have been reported in 0.2% of 2799 patients receiving KEYTRUDA. Monitor for signs and symptoms of infusion-related reactions. Interrupt or slow the rate of infusion for Grade 1 or Grade 2 reactions. For Grade 3 or Grade 4 reactions, stop infusion and permanently discontinue KEYTRUDA.

Complications of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Fatal and other serious complications can occur in patients who receive allogeneic HSCT before or after antiPD-1/PD-L1 treatments. Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute and chronic GVHD, hepatic veno-occlusive disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between antiPD-1/PD-L1 treatments and allogeneic HSCT. Follow patients closely for evidence of these complications and intervene promptly. Consider the benefit vs risks of using antiPD-1/PD-L1 treatments prior to or after an allogeneic HSCT.

Increased Mortality in Patients With Multiple Myeloma

In trials in patients with multiple myeloma, the addition of KEYTRUDA to a thalidomide analogue plus dexamethasone resulted in increased mortality. Treatment of these patients with an antiPD-1/PD-L1 treatment in this combination is not recommended outside of controlled trials.

Embryofetal Toxicity

Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman. Advise women of this potential risk. In females of reproductive potential, verify pregnancy status prior to initiating KEYTRUDA and advise them to use effective contraception during treatment and for 4 months after the last dose.

See more here:
Merck Presents Results From Head-to-Head Phase 3 KEYNOTE-598 Trial Evaluating KEYTRUDA (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA...

Read More...

Family of Belfast woman Eimear Gooderham (25) share memories and dealing with grief in special UTV programme – Belfast Telegraph

Monday, February 1st, 2021

The story of Belfast woman Eimear Gooderham (nee Smyth), who passed away after a brave battle with cancer and sparked awareness of the stem cell register in Northern Ireland, will be told in a UTV programme this week.

imear was diagnosed with Hodgkins Lymphoma, a type of blood cancer, in 2016 aged 22 and underwent a dozen rounds of chemotherapy.

She manage to beat the cancer in the spring of 2017 and was given the all-clear by doctors, only for the disease to return again a few weeks later.

The disease went into remission following an autologous stem cell transplant, which involved using her own cells and high-dose chemotherapy.

In 2018, however, the Hodgkins Lymphoma returned once again and doctors said Eimear required another stem cell transplant, but from an anonymous donor.

This prompted her father Sean to launch a campaign, alongside UTV, to get people to sign the stem cell register and eventually a match was found.

Eimear had surgery, but sadly she passed away in hospital of organ failure on June 27, 2019, after suffering complications.

She had been due to marry her fianc Phillip Gooderham in October 2019, however with her condition worsening the wedding was organised to take place in hospital before she passed away.

UTV presenter Sarah Clarke followed Eimears story from the summer of 2018 and now that story will be told in a special programme, Eimears Wish, airing this Thursday at 10.45pm.

The programme will feature extracts from her video diary and dad Sean and sister Seainin, share memories of Eimear and talk about the positive ways they have been dealing with their grief since she passed away.

Sean Smyth said he hopes the programme will highlight the need for more people in Northern Ireland to join the stem cell donor register, especially men aged between 16 and 30.

There is also a lack of age-appropriate care for teenagers and young adults with life threatening illnesses such as blood cancer, he said.

The current facilities and the environment in which our teenagers and young adults receive their treatment and care is very poor. There also needs to be better facilities for the childrens carers.

Sarah Clarke added: It was Eimears dying wish to raise awareness of stem cell donation and to help further research into the treatment to help others. And although this programme is an entirely different one from the one we set out to make, I hope that it will in some way help to do that.

Belfast Telegraph

See the original post:
Family of Belfast woman Eimear Gooderham (25) share memories and dealing with grief in special UTV programme - Belfast Telegraph

Read More...

Disabled People Are Waiting, Anxiously, For Lifesaving Covid-19 Vaccinations – Forbes

Monday, February 1st, 2021

getty

On January 26, 2021, Governor Gavin Newsom announced that California would alter its previous plan to start offering vaccines to high risk adults under 65 in the next vaccination phase. Instead, future eligibility levels in the state will be determined solely by age.

The United States Centers for Disease Controls current non-binding recommendation is to offer vaccines to disabled and chronically ill people aged 1664 years with underlying medical conditions which increase the risk of serious, life-threatening complications from COVID-19 in Phase 1c. In many states that would mean eligibility in a month or two, once the current first phases are completed. That was the plan for California, too, until this past week.

This move in California deeply disappointed the disabled community, and intensified growing concern among disabled and chronically ill people nationwide.

In a January 28 press conference, Andy Imparato, Executive Director of Disability Rights California, explained that based on current rates of vaccine production, going strictly by age will mean disabled and chronically ill people wont have access until June.

Another speaker at the virtual press conference, San Francisco disabled activist Alice Wong, has been both profoundly affected by the Covid-19 pandemic, and active in drawing attention to the unique risks and hardships the virus poses to people with disabilities and chronic illnesses. Californias change in vaccination priorities spurred her to further action:

"When I found out that Governor Newsom was eliminating prioritization for groups under Phase 1C in the state's vaccination plan I felt a surge of rage and fear at the injustice of it all. In response, I tweeted with the hashtag #HighRiskCA as a way for people from multiple communities disproportionately impacted by the pandemic to share their stories.

This is a localized variation on a hashtag thats been active since the pandemic started in March 2020, #HighRiskCovid19. Another important hashtag that has since the beginning expressed the feelings of high risk populations is #NoBodyIsDisposable.

Other disabled people also spoke out at the January 28 press conference.

Elena Escalera, Ph.D. of St. Mary's College and the #NoBodyIsDisposable Coalition said that the prospect of being included in the next phase of vaccinations is encouraging to people with disabilities and chronic illnesses. But when those priorities were changed in California to leave out people with disabilities under 65, ... there went the glimmer of hope of survival.

Anesthesiologist and bioethicist Dr. Alyssa Burgart highlighted the deep disability bias at the core of these decisions.

The bias against people with disabilities is pervasive. It is pervasive in health care because many of these folks are largely invisible. As you can see, many of these speakers have been confined to their homes because of the pandemic, and how much this has truly limited their ability to be engaged.

And Claudia Center, Legal Director of the Disability Rights Education and Defense Fund, noted the multiple layers of disability and chronic illness discrimination that disabled and chronically ill people have faced throughout the pandemic, and which also intersect with racial and other biases. These issues have included not just the latest setbacks in vaccine prioritization, but also denial of Covid-19 treatment through crisis standards of care, disabled people not being allowed to bring essential support staff with them to the hospital, and lack of data collection on how the pandemic affects disabled people.

It seems like California is making this change in priorities so it can avoid complicated and subtle decision-making, and instead go by more easily confirmed age. If so, it will achieve this simplicity by throwing some of its highest risk populations under the proverbial bus. Whatever the reasons for this change, and whether or how long its current priority system stands, it is adding to an already tense undercurrent of feeling among people with disabilities all over the country. There is a growing fear and conviction that disabled and chronically ill people, and our very specific kinds of risk from COVID-19, are once again being misunderstood and overlooked.

Obviously, everyone who isnt a vaccine or Covid skeptic is anxious to get vaccinated for the virus. And we all face the same fundamental barriers to vaccination, such as lack of sufficient supply and clumsy distribution systems. Its also important to recognize that putting any group higher on a priority list by itself doesnt do much. You can be at the top of the list, but if you cant figure out how to get a shot, or if your local provider runs out of doses, you are out of luck.

However, disabled and chronically ill people generally have more reason than most to be anxious and impatient. Some specific disabilities and conditions dont put people at that much more of a risk from Covid-19 infection, serious illness, or death, but a great many do. This is not mere speculation or paranoia. It is a documented medical fact recognized by most medical and epidemiological authorities.

Plus, being disabled exposes us to other, less direct hardships from the pandemic. For one thing, disabled people are more likely to be institutionalized in congregate care like nursing homes, assisted living, and group homes making it impossible for us to isolate ourselves. Many others of us require home care, which is less risky than nursing homes, but still exposes us to vectors of infection that we cant really do much on our own to avoid.

In a Los Angeles Times Op-Ed, Tim Jin writes:

Many people with disabilities are dealing with comorbidities of health that make us more vulnerable if we get the virus, while routine contact with multiple caregivers and other people who support us increases our risk of being exposed to COVID-19 As a person with cerebral palsy who lives on my own with support, I am more at risk because I rely on my staff to help me. I am exposed to multiple support people who come and go each day.

And Its not just people with conditions conventionally seen as disabilities who face higher risk from Covid-19. In an article for CNN, organ transplant recipient Kendall Ciesemier underscores the risk to people with chronic illnesses and other specific medical conditions:

The ones with cancer, with HIV, who have recovered from a bone marrow, stem cell, or solid organ transplant are increasingly becoming deprioritized across the country, sent to the back of the vaccine line.

She adds that these more recent setbacks only add to the sense of hopeless invisibility disabled, chronically ill, and other marginalized people have experienced throughout the pandemic:

To me and many like me, living in this pandemic has provided a daily reminder that our needs are unseen to those around us, that our lives hold little value to those who refuse to wear masks, who gather in groups or fly to a vacation destination. This is especially true for immunocompromised Black and brown people, who are among the most marginalized.

As disabled and chronically ill people we arent saying we have to be the very highest priority. We also recognize that other groups, particularly the elderly, have also at various points during the pandemic been ill-served, forgotten, or written off as acceptable losses. Most of us agree that prioritizing elderly people and healthcare workers makes sense. But we are dismayed to see disabled people who dont fit these categories seemingly forgotten.

Prioritizing everyone over 65 or 75 certainly puts some disabled people at the front of the line. But while many elderly people are also disabled, most disabled people are not elderly. According to the U.S. Census, about 34% of Americans over 65 have some kind of disability, a substantially higher disability rate than for the overall population. But only about 27% of Americans with disabilities are over 65. Disability and age overlap, but only partly.

Likewise, prioritizing health care and congregate care employees and residents is important to the disabled community, but only addresses some of us, not the vast majority who dont live in these facilities. Everyone knows about the tragedy of infection and death in nursing homes. Fewer people realize the same risk to developmentally disabled people in large institutions and smaller group homes. Meanwhile, people with disabilities who live on their own, or at home with home care, are virtually forgotten.

As a result, while we are nominally recognized to be high risk, most states vaccine priorities fail to recognize people with disabilities and chronic health conditions as a priority. Despite CDC recommendations, only 6 states currently offer vaccines to high risk adults who arent either elderly or health care / long term care workers. Many of us face the real possibility of our high-risk conditions not being recognized at all, resulting in more unnecessary illness, death, and long-term suffering.

Given the present scarcity of vaccine doses though, what is the fairer answer? This question is often presented as a false choice between deciding when to vaccinate disabled people based on science, and giving priority to the disability community for social or political reasons. In fact, it should be a combination of the two.

Scientists may know better which specific chronic illnesses and disabilities are and arent higher risk for Covid-19. But they arent always good at knowing and remembering the other ways Covid-19 disproportionately affects and endangers disabled and chronically ill people. One reason why a lot of disabled people are getting not just anxious but angry is that so many of us know from experience that without our own deliberate advocacy, its entirely possible for disabled and chronically ill people to be simply overlooked.

Deciding in a more targeted way who should have earlier access to Covid-19 vaccines is hard. Nobody is saying its not. But simply going by age, or focusing on a few specific environments and professions, isnt the answer. Its not logical, scientific, or humane.

On the other hand, the new Biden Administration appears to be a little bit ahead of the game in recognizing disabled and chronically ill peoples higher risk, and making them a higher priority. Its initial Covid-19 proposals include:

Implementation is always difficult, but a few more basic recommendations arent hard to think of. For example:

Among the many fears generated by the Covid-19 pandemic, one affecting the disabled community from the start is that our fellow Americans and portions of our government just dont care as much if we die. This idea has its roots in over a hundred years of on and off enthusiasm for eugenics the idea that society is better off without disabled people, and that disabled people themselves are, in a sense, better off dead.

A more specific fear and a profound sense of insult took hold in the early days of the pandemic when the fact that elderly and disabled people were at much higher risk of death was reported as a way to reassure other Americans that at least they werent in danger. This also turned out to be untrue, but even if it had been, it was not a proud moment in the history of American bravery or solidarity. Things only looked worse when states and localities proposed rationing policies that would deny care to people with certain kinds of disabilities who got Covid-19 explicitly and in policy writing them off.

Now its already looking like the vaccine rollout might sacrifice or simply overlook disabled people. Its probably still an exaggeration to say, as many disabled people are saying now, on social media and elsewhere, They want us dead. But the slightly less dramatic assertion that They dont care about us honestly doesnt seem far fetched these days. And even if we have our fellow Americans and governments intentions all wrong, their actions have not been promising.

Theres still time for a turnaround, but that time is running out fast.

See the article here:
Disabled People Are Waiting, Anxiously, For Lifesaving Covid-19 Vaccinations - Forbes

Read More...

Single-cell molecular profiling of all three components of the HPA axis reveals adrenal ABCB1 as a regulator of stress adaptation – Science Advances

Monday, February 1st, 2021

Abstract

Chronic activation and dysregulation of the neuroendocrine stress response have severe physiological and psychological consequences, including the development of metabolic and stress-related psychiatric disorders. We provide the first unbiased, cell typespecific, molecular characterization of all three components of the hypothalamic-pituitary-adrenal axis, under baseline and chronic stress conditions. Among others, we identified a previously unreported subpopulation of Abcb1b+ cells involved in stress adaptation in the adrenal gland. We validated our findings in a mouse stress model, adrenal tissues from patients with Cushings syndrome, adrenocortical cell lines, and peripheral cortisol and genotyping data from depressed patients. This extensive dataset provides a valuable resource for researchers and clinicians interested in the organisms nervous and endocrine responses to stress and the interplay between these tissues. Our findings raise the possibility that modulating ABCB1 function may be important in the development of treatment strategies for patients suffering from metabolic and stress-related psychiatric disorders.

The hypothalamic-pituitary-adrenal (HPA) axis is pivotal for the maintenance of homeostasis in the presence of real or perceived challenges (1, 2). This process requires numerous adaptive responses involving those of the neuroendocrine and central nervous systems (3). When a situation is perceived as stressful, the paraventricular nucleus (PVN) of the hypothalamus releases corticotropin-releasing factor (CRF) to the hypophyseal portal system, connecting the hypothalamus with the anterior pituitary gland, where it stimulates the secretion of adrenocorticotropic hormone (ACTH) into the peripheral bloodstream. In turn, upon binding to the melanocortin 2 receptor, ACTH stimulates the production and secretion of glucocorticoids (GCs) from the adrenal cortex that bind to corticosteroid receptors (4). These act as transcriptional regulators providing the necessary energy resources and behavioral (emotional and cognitive) adaptations to cope with the stressful challenge and also to exert the main negative feedback at different levels of the HPA axis. While necessary for immediate response, prolonged GC exposure can increase morbidity and mortality (5, 6). Dysregulation of the neuroendocrine stress response can have severe psychological and physiological consequences, and chronic activation of the HPA axis has been linked to stress-related disorders such as anxiety disorders, major depression, posttraumatic stress disorder, and metabolic syndrome (7). As exemplified in Cushings syndrome, endogenous overproduction of GCs has detrimental effects such as impaired glucose metabolism; infectious, musculoskeletal, and cardiovascular complications; and neuropsychiatric comorbidities (8). However, despite decades of research, the molecular underpinnings of HPA dysfunction after prolonged exposure to stress are still not fully understood. Furthermore, most of the work in the field has largely focused on investigating chronic stress effects in the brain, yet much less is known about how chronic stress exposure affects the peripheral components of the HPA axis at the molecular level (9). Recent advances in the field of genomics now allow us to obtain genome-wide data on an individual cell level. Single-cell transcriptomics thereby provide powerful insight into the complexity of different tissues by enabling the identification and characterization of molecular signatures at extraordinary resolution, which can ultimately reveal previously unidentified dimensions of cell identities and their relationships with disease (10).

In this study, using single-cell RNA sequencing (scRNA-seq), we comprehensively cataloged transcriptional changes associated with chronic stress exposure in all three components of the HPA axis. We analyzed 21,723 single cells from the PVN, the pituitary, and the adrenal gland from 10 mice across two conditions (controls, n = 5; stress, n = 5). We found cell typespecific transcriptional signatures of chronic stress adaptation across the HPA axis. We identified a novel subpopulation of stress-responsive adrenocortical cells, which play an important role in the plasticity and adaptation process associated with chronic stress exposure in the adrenal cortex. We validated our findings using mouse tissues, human adrenal samples from patients with ACTH-dependent Cushings syndrome, in vitro adrenal cell models, and peripheral cortisol and genotyping data from treatment-nave, depressed patients. Our study provides the first unbiased and systematic characterization of cell typespecific signatures of the HPA axis under baseline (unstressed) and chronic stress conditions. Furthermore, our results allow a deeper understanding of HPA axis activity and its association with stress-related and metabolic disorders. Ultimately, these findings could lead to more accurate, and more reliable, molecular signatures to monitor disease progression and efficacy of treatment.

To induce chronic activation of the HPA axis, we used the chronic social defeat stress (CSDS) model, a validated, commonly used paradigm to induce long-lasting, depression- and anxiety-like endophenotypes in mice (Fig. 1A) (11). Stress exposure resulted in hallmark features of chronically stressed mice, including reduced social interaction, as demonstrated by the social avoidance test (SAT), a significant increase in basal corticosterone (CORT) levels, enhanced adrenal weight, and reduced fur quality, which is a measure associated with decreased grooming behavior (Fig. 1, B to F) (12). Body weight was not significantly different across groups after CSDS (Fig. 1G). Notably, the natural variability shown by control (unstressed) mice in the SAT did not correlate or was indicative of any of the hallmark features of chronically stressed mice (fig. S1). Five mice from each group (controls versus stressed) were selected for molecular characterization. The PVN, pituitary, and adrenal gland from these mice were used for scRNA-seq experiments (Fig. 1H).

(A) Experimental timeline of chronic social defeat stress (CSDS) paradigm for control (n = 15) and stressed (n = 15) mice. (B) CSDS reduced interaction ratios in stressed mice during the social avoidance test. Bigger dots represent the five mice from each group selected for molecular characterization (P = 0.0084, unpaired t test, two-tailed). (C and D) Twenty-one days of social defeat exposure significantly increased (a.m.) basal corticosterone (CORT) levels (P < 0.0001, unpaired t test, two-tailed) and enhanced adrenal weight (P < 0.0001, unpaired t test, two-tailed). (E) Representative adrenal glands from control and stressed mice. Scale bars, 0.5 mm. (F) CSDS significantly reduced fur quality in stressed mice [two-way analysis of variance (ANOVA), P < 0.0001]. Coat state score: (0) no wounds, well-groomed and bright coat, and clean eyes; (1) no wounds, less groomed and shiny coat OR unclean eyes; (2) small wounds, AND/OR dull and dirty coat and not clear eyes; (3) extensive wounds, OR broad piloerection, alopecia, or crusted eyes. (G) Body weight was not significantly affected by chronic stress (two-way ANOVA, P > 0.05). (H) Experimental design for scRNA-seq experiment. Individual cell suspensions were prepared from the PVN, pituitary gland (PG), and adrenal gland (AG) from selected control (n = 5) and stressed mice (n = 5). **P < 0.01, ****P < 0.0001.

To characterize inter-and intratissue heterogeneity of the HPA axis, we sequenced the transcriptome of 21,723 single cells from the PVN, pituitary, and adrenal, obtained from both unstressed (n = 5) and chronically stressed (n = 5) mice. We systematically cataloged cell identities using Scanpy, a scalable toolkit for analyzing single-cell gene expression data (13) following best practices. Graph-based clustering was performed to group cells according to their unique gene expression profiles, and dimension reduction (UMAP, Uniform Manifold Approximation and Projection) plots were used for visualization (Fig. 2) (14). In the PVN, unsupervised cluster analysis revealed a total of 18 cell clusters with distinct gene expression signatures (Fig. 2A). We determined the identity of each cluster based on the expression of established cell typespecific markers from the literature (1520). Expression of these markers across all PVN clusters can be found in fig. S2 (A to D). The 18 clusters from the PVN were further subdivided into eight major cell types as neurons, oligodendrocytes, astrocytes, microglia, endothelial, ependymal, tanycytes, and vascular cells (Fig. 2B). In the pituitary, we identified 22 unique cell clusters across 12 populations, which were grouped into somatotropes, lactotropes, corticotropes, melanotropes, gonadotropes, thyrotropes, stem cells, Pou1f1-expressing mixed cells, macrophages, endothelial cells, vascular cells, and posterior pituitary cells (Fig. 2, C and D, and fig. S3, A and B). Last, in the adrenal gland, we identified 16 unique clusters grouped into eight major groups of cells from the zona glomerulosa, zona fasciculata, a transition zone of cortical cells, medullar cells, capsular and vascular cells, macrophages, endothelial cells, and a small cluster of unknown cells (Fig. 2, E and F, and fig. S4, A and B). Expression of the top 100 genes defining the individual clusters in each of the three tissues can be found in tables S1 to S3.

(A) Dimensionality reduction Uniform Manifold Approximation and Projection (UMAP) plot depicting 6966 single cells from the PVN of the hypothalamus. Colors represent each of the 18 Louvain groups of individual cell types labeled with an abbreviation as follows: glutamatergic neurons (nGLUT1 and nGLUT2), GABAergic neurons (nGABA1 and nGABA2), mixed neurons (nMixed), vasopressin neurons (nAVP), neuropeptides (nNeuP), oligodendrocytes (Oligo1 and Oligo2), committed oligodendrocyte progenitor cells (COPs), oligodendrocyte progenitor cells (OPCs), astrocytes, endothelial, microglia, macrophages, ependymal, tanycytes, and vascular cells. (B) Distribution and percentage of eight major cell types in the PVN (purple). (C) UMAP plot depicting 9879 single cells from the pituitary. Colors represent each of the 22 Louvain groups representing individual cell types labeled with an abbreviation as follows: somatotropes (Somato1 to Somato8), lactotropes (Lacto1 and Lacto2), corticotropes (Cortico1 and Cortico2), melanotropes, gonadotropes (Gonado1 and Gonado2), thyrotropes (Thyro), endothelial, macrophages, vascular cells, stem cells, Pou1f1 mixed cells (Pou1g1 MCs), and posterior pituitary cells (PPCs). (D) Distribution and percentage of 12 major cell types in the pituitary (green). (E) UMAP plot depicting 4878 single cells from the adrenal. Colors represent each of the 16 Louvain groups representing individual cell types labeled with an abbreviation as follows: zona fasciculata (zFasc1 to zFasc5), zona glomerulosa (zGlom1 and zGlom2), transition zone of mixed fasciculata and glomerulosa cells (tZone1 and tZone2), cycling adrenocortical cells (cACCs), macrophages 1 and 2, endothelial, medullar cells, capsular and vascular cells, and unknown cells. (F) Distribution and percentage of eight major cell types in the adrenal (blue).

Next, we performed inter- and intratissue analyses to characterize cell typespecific molecular signatures of chronic stress in all three tissues of the HPA axis. First, we assessed the distribution of cell numbers for each cluster by comparing the total number of cells from the stressed group to controls (Fig. 3, A to C, and fig. S5, A to C). In the PVN, we observed a significant decrease in the number of cells from the Glut2 (32%) and neuropeptide (25%) neuronal clusters (Fig. 3A). In the pituitary, we found a significant increase in two subclusters of somatotropes (Somato6 and Somato8, 67 and 69%, respectively) (Fig. 3B). Last, in the adrenal gland, we identified the largest and most significant changes in cell distribution between the two groups. Specifically, we observed a significant increase in the number of zona fasciculata 1 cells (82%) and macrophages 2 (70%), as well as a significant decrease in the number of zona glomerulosa 1 cells (40%) (Fig. 3C).

(A to C) Distribution of cell numbers by cluster in each condition (control versus stress). Bars represent the percentage of cells from the control and stressed group per cluster (0 to 100%). All controls (gray), PVN (purple), pituitary (green), and adrenal (blue). Fishers exact test *P < 0.05, **P < 0.01, ***P < 0.001. (D) Sixty-six DEGs in 10 clusters of the PVN. Dark purple represents neurons, purple represents glial cells, and light purple represents vascular cells. (E) Six hundred ninety-two DEGs in 17 clusters of the pituitary. Dark green represents endocrine cells, green represents support cells, and light green represents stem/progenitor cells. (F) Nine hundred twenty-two DEGs in 10 clusters of the adrenal gland. Dark blue represents endocrine cells and light blue represents support cells. Size of the circle represents the number of DEGs in each cluster for all three tissues. (G) DEGs across tissues (intertissue analysis). Sixteen DEGs in common (PVN, pituitary, and adrenal), 3 DEGs (PVN and pituitary), 6 DEGs (PVN and adrenal), and 97 DEGs (pituitary and adrenal). Fourteen DEGs exclusively in the PVN (purple), 162 DEGs exclusively in the pituitary (green), and 343 DEGs exclusively in the adrenal gland (blue). Size of the circle represents the total number of DEGs in each cluster for all three tissues. (H) Expression patterns of dysregulation across DEGs per tissue. Heatmaps represent the percentage of up- and down-regulated DEGs per cluster within the PVN (purple), pituitary (green), and the adrenal (blue). Heatmap scale, 0% (gray); 50% (white); 100% (dark purple/green/blue).

Subsequently, we performed differential expression analyses to evaluate cell typespecific molecular signatures of chronic stress. We compared differentially expressed genes (DEGs) within tissues (intratissue analysis) and found that no single gene was differentially expressed (DE) across all cell types for any of the three tissues (tables S4 to S9), suggesting that cell typespecific effects of chronic stress could be masked or diluted in alternative studies using bulk RNA-seq. In contrast, when gene expression was analyzed within cell types, interesting effects emerged. In the PVN, we identified a total of 66 DEGs in 10 of the 18 cell types (Fig. 3D). In the pituitary, our analysis revealed a total of 692 DEGs in 17 of the 22 pituitary clusters (Fig. 3E). Consistent with cell distribution changes by condition, in the adrenal gland, we also observed the largest number of DEGs. Specifically, we identified 922 DEGs in 10 of the 16 adrenal clusters, ranging from 21 to 171 DE transcripts per cell type (Fig. 3F). A full list of DEGs per cell type across all three tissues can be found in tables S4 to S6.

We further compared DEGs across tissues (intertissue analysis). First, we collapsed all DEGs per tissue and identified 39 unique DEGs in the PVN, 278 in the pituitary, and 462 in the adrenal. We then looked for common genes and found 16 DEGs across all tissues (Fig. 3G). There were also 6 DEGs in common between the PVN and the adrenal, 3 DEGs between the PVN and the pituitary, and 97 DEGs between the pituitary and the adrenal glands. In addition, there were 14 genes exclusively DE in the PVN, 162 in the pituitary, and 343 in the adrenal gland (Fig. 3G and table S10). Among the genes dysregulated across the three tissues, we found several genes coding for protein members of the GC receptor (GR) chaperone complex known to play key roles in the stress response (21). Among these were HSP90 (Hsp90aa1 and Hsp90ab1), which is responsible for the direct binding of GR to the chaperone complex; HSP70 (Hspa1a and Hspa8), which encodes the first protein that recognizes and binds newly synthesized GR; and HSP40 (Dnaja1 and Dnajb1), which mediates the interaction between GR and its chaperones (22). We also observed consistent differences between the PVN and the adrenal gland for the transcription factor Nfkbia (NFB), known to interact with GCs due to their strong anti-inflammatory properties (22, 23), and Fkbp4 (encoding for the FKBP52 protein), a major regulator of GR activity (table S10) (23, 24).

Moreover, we found that most cell populations in the PVN and the pituitary showed an up-regulation of DEGs after exposure to chronic stress, except for microglial cells (PVN), macrophages, and vascular cells (pituitary), where DEGs were down-regulated (Fig. 3H). In the adrenal gland, we noticed a different pattern of regulation with several cell types, including macrophages and adrenocortical cells, showing a down-regulation of DEGs after exposure to chronic stress (Fig. 3H), suggesting a larger range of transcriptional plasticity after chronic stress at the adrenal level. Overall, these results suggest that the most profound differences due to chronic stress in the HPA axis occur in the adrenal gland, where our intra- and intertissue analyses identified the largest number of DEGs and the most significant changes at the cell population level.

The adrenal gland is a highly dynamic organ, which can quickly adapt and regenerate in response to different types of stimuli (25). For example, the adrenal significantly increases its weight in response to chronic stress, a phenomenon that has been documented in rodents, as well as human psychiatric patients (2628). In our study, we confirmed a significant increase of the adrenal weight of mice exposed to chronic social stress (Fig. 1, D and E), and single-cell transcriptomic analyses of the adrenal gland revealed a specific population of overrepresented zona fasciculata cells within the stressed group (zFasc1) (Fig. 3C). In an attempt to further investigate zFasc1 cells and identify what makes them unique, we compared their molecular profiles against all other cells in the adrenal. Because this population was so strongly driven by stress, we reasoned that the genes defining this cell type are also important responders to chronic stress. We found that the top three genes that defined the zFasc1 population were the adenosine 5-triphosphate (ATP)binding cassette subfamily B member 1B (Abcb1b) [qval: 3.27 10146; fold change (FC): 7.4], Suprabasin (Sbsn) (qval: 4.08 1084; FC: 6.6), and the 5-reductase (Srd5a2) (qval: 7.78 1082; FC: 5.8) (Fig. 4A, table S3, and fig. S5D). These genes have been previously associated with GC transport (29, 30), cell proliferation (31), and glucose metabolism (32). To validate our findings and to rule out any potential bias introduced by single-cell dissociation methods that can affect the proportions of cells in the original intact tissue, we performed mRNA in situ hybridization of Abcb1b, Sbsn, and Srd5a2 using RNAscope in adrenal glands obtained from nave or chronically stressed mice. Consistent with our single-cell results, the expression of these genes was restricted to adrenocortical cells from the zona fasciculata (Fig. 4B). Moreover, we observed a significant increase of Abcb1b and Sbsn, but not Srd5a2, mRNA expression in the zona fasciculata of stressed mice as compared to controls (Fig. 4, C to E).

(A) UMAP plot showing the expression of the top three genes that differentiate zFasc1 from other zFasc clusters: Abcb1b, Sbsn, and Srd5a2. Cyp11b1 is expressed in all zona fasciculata cells (zFasc1 to zFasc5). (B) Expression of Abcb1b, Sbsn, and Srd5a2 is restricted to adrenocortical cells from zona fasciculata. Representative adrenal glands from control and stressed mice, showing mRNA expression (brown) of Abcb1b, Sbsn, and Srd5a2 by RNAscope. Nuclei were stained with vector hematoxylin QS (purple). Scale bars, 500 m. (C to E) Chronic stress leads to a significant increase of Abcb1b (P < 0.0002) and Sbsn (P < 0.0005), but not Srd5a2 (P = 0.9715), mRNA expression in the zona fasciculata of stressed (n = 14) as compared to control (n = 14) mice. Representative images show the percentage of mRNA expression (brown) and nuclei (purple). Scale bars, 50 m. (F) CSDS leads to cellular hypertrophy in the adrenal cortex of chronically stressed mice (P < 0.0001). Bar graphs represent the average number of nuclei from the zona fasciculata. Average cell area was calculated by dividing the number of nuclei by the total area. Values are multiplied by 1000 for graphical representation. (G and H) Hypertrophy in the adrenal cortex is associated with higher levels of Abcb1b mRNA expression. Bar graphs represent the average number of nuclei present in areas of high Abcb1b (P < 0.0001) and Sbsn (P = 0.9628) mRNA expression as compared to low expressing regions in zona fasciculata of stressed mice (n = 11). All unpaired t tests, two-tailed. ***P < 0.001, ****P < 0.0001.

Subsequently, we tested whether the increase in adrenal weight after chronic stress exposure was due to an increase in the number of cells (hyperplasia) or an increase in the size of cells (hypertrophy) at the adrenal cortex. Our analysis revealed that, in stressed mice, the number of nuclei present in the zona fasciculata was significantly lower as compared to controls (Fig. 4F), suggesting cellular hypertrophy in the adrenal cortex of chronically stressed mice. Last, we evaluated whether growth characteristics of zona fasciculata cells with high expression levels of Abcb1b or Sbsn were different from low-expressing cells. Unexpectedly, our analysis revealed that the number of nuclei present in areas with high Abcb1b expression was significantly lower than in regions with low Abcb1b expression (Fig. 4G). We did not find any differences in nuclei density between regions of high or low Sbsn expression (Fig. 4H). These results suggest that hypertrophy in the adrenal cortex is associated with higher levels of Abcb1b mRNA expression.

Next, we investigated how the adrenal expression levels of Abcb1b, Sbsn, and Srd5a2 change over time, during 21 days of chronic stress exposure. Therefore, we exposed six groups of mice to a different number of social defeat sessions (0, 3, 5, 10, or 21 days). An additional group of mice received 21 days of social defeat, followed by 48 hours of recovery time to match the end point of our original CSDS paradigm (23 days) (Fig. 5A). We observed a significant and gradual increase in adrenal weight across time points (Fig. 5B). Three days of social defeat were sufficient to stimulate a significant increase in adrenal weight, which continued steadily and plateaued between days 10 and 21. We then quantified bulk mRNA expression levels of Abcb1b, Sbsn, and Srd5a2 in the adrenal cortex from these mice using quantitative real-time polymerase chain reaction (qRT-PCR). We found a significant increase of Abcb1b mRNA levels after 5 days of social defeat, while an increase for Sbsn was present only after 21 days (Fig. 5C). Consistent with our in situ nuclei quantification, we also identified a significant correlation between adrenal weight gain and the expression levels of Abcb1b (r = 0.73; P < 0.0001) and Sbsn (r = 0.51; P = 0.004) (Fig. 5D), suggesting that increases in the expression of these genes were proportional to increases in adrenal weight. In contrast, Srd5a2 did not yield any significant results in these experiments (Fig. 5, C and D). We did not find any significant differences in adrenal weight or mRNA expression levels of these genes between days 21 and 23, suggesting that the long-lasting effects of the CSDS paradigm are still present 48 hours after the last defeat session. Last, our results suggest that chronic stress exposure causes zona fasciculata cells to enlarge and increase their expression of Abcb1b, perhaps as a mechanism to cope with the increased production of GCs in the system.

(A) Experimental timeline. Six different groups of mice (n = 5) were exposed to a different number of social defeat sessions. (i) Controlno defeat, (ii) 3 days, (iii) 5 days, (iv) 10 days, (v) 21 days, and (vi) 21 days, followed by 48 hours of recovery time. (B) Three days of social defeat are sufficient to stimulate a significant increase in adrenal weight, which continued steadily and plateaued between days 10 and 21 (P < 0.0001). (C) Social defeat exposure leads to a significant increase of Abcb1b mRNA levels after 5 days of social defeat (P < 0.0001), an increase of Sbsn after 21 days (P < 0.001), while no significant changes in Srd5a2 expression (P = 0.12). Bar graphs represent mRNA levels of Abcb1b, Sbsn, and Srd5a2 normalized to Hprt. qRT-PCR, quantitative real-time polymerase chain reaction. (D) Social defeat leads to a significant correlation between adrenal weight gain and mRNA levels of Abcb1b (Pearson r = 0.73; P < 0.0001) and Sbsn (r = 0.51; P = 0.004), but no correlation with Srd5a2 expression (r = 0.29; N.S., no significance. P > 0.05). ***P < 0.001, ****P < 0.0001. CTRL, controls; SD, social defeat; D, day.

The Abcb1 gene, also known as multidrug resistance protein 1 (MDR1) or P-glycoprotein 1 (P-gp), is a well-characterized, ATP-dependent efflux pump, whose role is to transport xenobiotics and endogenous cellular metabolites across cellular membranes (33). The protein product of Abcb1 is encoded by two gene variants in mice (Abcb1a and Abcb1b) but only one gene in humans (ABCB1) (34). Moreover, it has been hypothesized that this gene modulates HPA axis activity and mediates antidepressant treatment response by regulating access of GCs and antidepressants into the brain (35). Most of the current literature in biological psychiatry has been primarily focused to understand the activity of Abcb1a in the brain, based on early observations that, in humans, the ABCB1 gene is highly expressed in endothelial cells of the blood-brain barrier (36). However, translational studies in rodents have not been successful in explaining how Abcb1 regulates the response to stress or antidepressant treatment (37). One of the reasons might be that most of these studies were carried out under the assumption that Abcb1a and Abcb1b have similar patterns of expression in the brain. Our single-cell analysis shows a very different picture with limited coexpression among the two variants. Abcb1a is specifically expressed in endothelial cells from the PVN and the pituitary (Fig. 6A), while Abcb1b is expressed in microglia and macrophages of all three tissues, in lactotropes and somatotropes of the pituitary, and in a subsection of zona fasciculata cells (zFasc1), where it shows its highest expression (Fig. 6A). Furthermore, we quantified the expression of Abcb1a and Abcb1b using publicly available bulk RNA-seq data from 35 different mouse tissues (38) and found that their expression also differs considerably in other peripheral organs. Abcb1a is lowly expressed in the periphery, while Abcb1b is the predominant variant showing high expression levels among multiple tissues, particularly in the adrenal gland where the expression of Abcb1b is several magnitudes higher as compared to every other tissue tested (Fig. 6B). These findings suggest that the adrenal gland is an important site for Abcb1 activity.

(A) UMAP plots representing cell typespecific mRNA expression of Abcb1a and Abcb1b in the PVN, pituitary, and adrenal gland of mice. (B) Bulk RNA sequencing data from 35 different mouse tissues showing mRNA expression levels of Abcb1a and Abcb1b. Heatmaps represent expression levels (0 to 12). Red, high expression; white, low expression. Expression values are displayed as Transcripts per Kilobase Million (TPM) and are log2-transformed.

Previous studies in rodents have shown that in vivo inhibition of Abcb1 by intraperitoneal injection of tariquidar, a highly specific and potent Abcb1a/b inhibitor (39), leads to a decrease in CORT levels after acute stress (40). Others have shown that mutant mice lacking both variants (Abcb1a/b) have lower baseline CORT levels as compared to wild-type controls (41). However, these studies could not attribute changes in CORT to a specific Abcb1 variant (Abcb1a or Abcb1b), nor could they conclude that the effects are modulated at the level of the brain or any of the peripheral tissues where Abcb1a and Abcb1b are expressed. To specifically explore the function of Abcb1b in the adrenal gland, we examined whether pharmacological inhibition by tariquidar modulates secretion of CORT in vitro, using an adrenocortical cell line. Mouse Y1 cells were stimulated for 24 hours with 10 nM forskolin alone, or in combination with different concentrations of tariquidar. Forskolin induces secretion of CORT by stimulation of adenylate cyclase (42). While 24 hours of forskolin treatment significantly increased CORT levels as compared to controls, we found a dose-dependent decrease of CORT with increasing concentrations of tariquidar (Fig. 7A), suggesting that GC secretion from adrenocortical cells might be dependent on Abcb1b function. In an attempt to translate our findings to humans, we assessed the modulatory role of ABCB1 on GCs, using human NCI-H295R adrenocortical cells, a validated in vitro model for steroid profiling based on their ability to produce and secrete the major steroidogenic enzymes of the adrenal cortex (43). In line with our previous results, treatment of NCI-H295R cells with 10 nM forskolin led to a significant increase of medium cortisol levels, as compared to vehicle-treated controls (Fig. 7B). Treatment with increasing concentrations of tariquidar led to a significant decrease of media cortisol levels (Fig. 7B). Together, our results show that in vitro pharmacological manipulation of Abcb1 in adrenocortical cell lines leads to a decrease in GC secretion, suggesting that modulation of Abcb1b in adrenocortical cells affects GC secretion in both mice and humans.

(A) Pharmacological inhibition of Abcb1 by tariquidar in mouse Y1 adrenocortical cells. CORT levels (ng/ml) after 24-hour treatment with forskolin (0 and 10 nM) or tariquidar (0, 10, 50, 125, 250, 500, and 1000 nM). (B) Pharmacological inhibition of ABCB1 by tariquidar in human NCI-H295R adrenocortical cells. Cortisol levels (ng/ml) after 24-hour treatment with forskolin (0 and 10 nM) or tariquidar (0, 10, 50, 125, 250, 500, and 1000 nM). One-way ANOVA, ****P < 0.0001.

In humans, chronic endogenous oversecretion of ACTH due to a pituitary or ectopic tumor results in excessive GC secretion and enlargement of the adrenal glands (Fig. 8A) (44). Thereby, this disease stage overlaps with the chronic activation of the HPA axis and hypersecretion of GCs in stress-related disorders. In cases of unsuccessful pituitary surgery or in those patients in whom the ectopic source of ACTH remains obscure, bilateral adrenalectomy is required to treat steroid excess. This opened the possibility to study adrenal glands that had been chronically stimulated and to compare those with controls in the absence of ACTH oversecretion. We quantified mRNA expression of ABCB1 and SBSN, using RNAscope in cases (n = 8) and controls (n = 6). SBSN mRNA was not detectable in human adrenocortical samples (Fig. 8B). Following this approach, we identified a significant up-regulation of ABCB1 mRNA in Cushings adrenocortical samples, as compared to controls (Fig. 8C). These results are consistent with our initial findings in chronically stressed mice and reinforce our evidence for a role of ABCB1 as a modulator of GC activity in the adrenal gland. In addition, our results highlight ABCB1 as a potential regulator of the detrimental effects of impaired glucose metabolism associated with patients with Cushings syndrome.

(A) Graphical representation of the effects of Cushings disease on the adrenal gland. (B and C) Expression of ABCB1 (P = 0.0056) and SBSN (P = 1.0) mRNA, using RNAscope in adrenal glands from patients with ACTH-dependent Cushings syndrome (n = 8) and controls (n = 6). Representative images show the percentage of mRNA expression (brown) and nuclei (purple) normalized by total area. Scale bars, 50 m, **P < 0.01.

Individuals who lack ABCB1, as it occurs in some breeds of dogs with the ABCB1-1 mutation (45), have severe adverse reactions to common medications that act as substrates of this transporter, such as immunosuppressants and steroid hormones (46). Previous studies have shown that dogs and rodents lacking a functional Abcb1/ABCB1 gene have a blunted HPA axis response compared to wild-type animals (41, 47). In humans, multiple single-nucleotide polymorphisms (SNPs) map to the ABCB1 gene locus, and some of these variants have been associated with reduced protein function and activity (48). One of the most studied ABCB1 polymorphisms is the rs2032582 (G2677T), which is a nonsynonymous variant on exon 21 that has been linked to major depressive disorder and treatment response (49). To investigate the relevance of our findings in depressed human patients, we examined whether the ABCB1 polymorphism rs2032582 is associated with an altered HPA axis response, using peripheral plasma samples from 154 treatment-nave, depressed patients. We measured plasma ACTH and cortisol concentrations in depressed patients at baseline, following CRF stimulation, and 15-min intervals for the following hour (Fig. 9A). The genotype and allele distributions of rs2032582 in patients are shown in Fig. 9A. At baseline, patients with the minor allele (TT) showed a decrease in cortisol levels as compared to the major (GG) and heterozygote (TG) alleles; however, this effect did not reach statistical significance after Bonferroni correction (Fig. 9B). After CRF stimulation, we found a significant genotype-by-time interaction in patients cortisol levels (qval: 0.033). More specifically, patients with the minor (TT) allele showed a dampened cortisol response after CRF stimulation (Fig. 9C). We did not find any statistical differences in ACTH levels after CRF stimulation (Fig. 9D), suggesting that the effects of rs2032582 on the ABCB1 gene might be taking place at the level of the adrenal gland. These results are consistent with our mouse and cell culture findings and support the idea that Abcb1/ABCB1 function may regulate HPA axis response.

(A) Experimental design. Predictors of remission in depression to individual and combined treatments (PReDICT) cohort (N = 154) to investigate effects of the ABCB1 variant rs2032582 on HPA axis function. CRF stim, CRF stimulation test; SNP, single-nucleotide polymorphism; HWE-P, Hardy-Weinberg equilibrium P value. (B) Baseline cortisol levels (g/ml) for treatment-nave, depressed patients carrying the rs2032582 SNP genotype. (C and D) Cortisol (g/ml) and ACTH (pg/ml) levels after CRF stimulation (log-transformed). Only completers were included in the analysis. There are no dropouts in sample sizes over time for cortisol or ACTH. GG = major homozygotes (n = 56), GT = heterozygotes (n = 74), TT = minor homozygotes (n = 24). Mixed effects models, Bonferroni-corrected *P < 0.05.

Despite decades of research, the molecular and cellular identity of the HPA axis components, their inter-relationships, and their function after chronic stress exposure are still only partially understood. Here, using scRNA-seq, we describe cell typespecific molecular signatures of chronic stress in all three components of the HPA axis, providing a level of resolution never before reached.

The PVN integrates and coordinates the neuroendocrine HPA axis response to stressful stimuli. However, aside from containing the neuroendocrine neurons that control the synthesis and release of CRF, the PVN also exhibits a significant degree of cellular and molecular complexity, with multiple types of neuronal and nonneuronal subtypes. In this study, we characterized and described the cellular heterogeneity and identity of all cell types in the PVN. We identified many DEGs that are involved in the intracellular trafficking of the GC and mineralocorticoid receptors and play key roles in the response to chronic stress, such as heat shock proteins and Fkbp4 across multiple cell types (24). We also found groups of genes that were DE in unique cell types, such as the cysteine-rich angiogenic inducer 61 gene (Cyr61), which was only found DE in ependymal cells. Cyr61 is a target gene of the hippo signaling pathway, which regulates tissue homeostasis, regeneration, proliferation, and growth and has recently been linked to the pathophysiology of stress-related psychiatric disorders (50). In the neuropeptide cluster, we found a down-regulation of corticotropin-releasing factor (Crf) and vasopressin (Avp), as well as an up-regulation of oxytocin (Oxt) and somatostatin (Sst); however, these changes did not survive correction for multiple testing. We did not find any significant dysregulation of GR (Nr3c1) mRNA in any of the clusters of the PVN. Nevertheless, we did find a significant difference in the total number of Nr3c1+ cells in some of the cell clusters of the PVN (fig. S2D), suggesting that the GR mRNA differences reported in the literature (4, 6, 9) could be due to a decrease in the total number of Nr3c1+ cells after chronic stress, rather than lower expression levels of the existing cells. A decrease in the total number of Nr3c1+ cells is not found across all cell types of the PVN but is rather limited to specific cell populations. These populations could represent the cell types where stress exerts its main effects in the PVN via GR. However, these findings would need to be further validated and replicated in other studies. Last, we found that most cell populations across the PVN showed an up-regulation of DEGs after exposure to chronic stress, except for microglial cells where most DEGs were down-regulated. These changes in microglial cells in combination with gene expression differences (across multiple cell types) of several genes involved in the intracellular trafficking of GCs are possibly the result of overexposure to GCs during a prolonged (chronic) stress paradigm. GCs are released during the stress response and are well known for their immunosuppressive and anti-inflammatory properties. In addition, growing evidence suggests that changes in neuroendocrine function and metabolism are significant triggers of inflammation, which has been linked to the development of neuropsychiatric disorders. Ultimately, while this is an important issue in the field, it is logistically challenging to address considering that the effects or stress, GCs, and inflammation are closely intertwined, likely powering each other in a bidirectional way.

The second component of the HPA axis, the pituitary gland, is a complex organ and an important regulator of major physiological processes, including the neuroendocrine stress response (51). It is composed of a heterogeneous mix of endocrine, general support, and stem cells (17, 18). Despite a significant body of research characterizing attributes of pituitary activity, the cell typespecific regulation of chronic stress at the pituitary level is still poorly understood. Here, we characterized cell typespecific molecular signatures of chronic stress in the pituitary gland. Among many, our DE analysis revealed several genes that were consistently dysregulated in multiple endocrine cells, such as somatotropes, gonadotropes, lactotropes, and corticotropes. Specifically, we found an up-regulation of Cd63, Hsp90aa1, and Hsp90ab1, as well as a down-regulation of several ribosomal genes in all four cell types, suggesting altered GC and ribosomal activity. Moreover, corticotropes are directly stimulated by CRF and are responsible for the release of ACTH into circulation. In our analysis, we found 32 DEGs in this population. However, we did not find any significant differences in the expression of the corticotropin-releasing hormone receptor 1 (Crhr1) or the GR (Nr3c1) gene. Furthermore, and consistent with our findings in the PVN, we found that most cell types across the pituitary showed an up-regulation of DEGs after exposure to chronic stress, except for macrophages and vascular cells, where most DEGs are down-regulated. In our single-cell data, we found a large number of DEGs across multiple types of endocrine cells, suggesting that the stress response in the pituitary gland is a dynamic and complex process that is not limited to the effect that CRF exerts on corticotropes. In our analyses, somatotropes were the population of pituitary cells that showed the biggest changes after chronic stress, both in terms of number of DEGs and changes in proportions of cells. Somatotropes produce and release growth hormone, and they play an important role in the regulation of GC synthesis and adrenal growth and have been shown to positively affect adrenal cell size and number of adrenocortical cells (52). However, the role that somatotropes play in chronic stress and the development of stress-related psychiatric disorders are still poorly understood. Our high-throughput, cell typespecific findings of the effects of chronic stress on the pituitary and somatotropes are both novel and a significant advancement to our understanding of the mechanisms of stress adaptation in the pituitary gland.

Last, the adrenal gland is a major effector of the HPA axis, where interplay between several types of specialized cells takes place to coordinate a complex endocrine, immune, and metabolic response to stress. It is composed of the adrenal medulla and the adrenal cortex, two embryonically different endocrine tissues (25). The adrenal cortex is further divided into three major zones: zona glomerulosa (zG), zona fasciculata (zF), and zona reticularis (zR), each responsible for the synthesis and release of mineralocorticoids, GCs, and androgens, respectively (27). Zona reticularis has been shown to be absent in mice (25). Until now, our understanding of the mechanisms responsible for chronic stress adaptation in the adrenal has been limited. Our study is the first to provide a cell typespecific, unbiased, molecular characterization of the adult adrenal gland (under baseline or chronic stress conditions). Across several cell types, we found a significant dysregulation of genes coding for steroidogenic enzymes responsible for the biosynthesis of corticosteroids, such as GCs and mineralocorticoids. More specifically, we found a dysregulation of Star, Fdx1, Cyp11b1, Cyp21a1, Cyp11a1, Hsd3b1, Nr4a1, and Agtr1a after exposure to chronic stress. In contrast to what we found in the PVN and pituitary, cell types in the adrenal showed both up-regulation and down-regulation of DEGs after exposure to chronic stress, suggesting a larger range of transcriptional plasticity after chronic stress at the adrenal level. Although the changes in the expression of genes coding for steroidogenic enzymes are consistent with the current literature (27), our results offer a new level of resolution by describing the specific cell types where these changes take place in the adrenal. Furthermore, our results highlight that changes after chronic stress in the adrenal are not limited to the endocrine cells of the adrenal cortex or adrenal medulla. In our data, we also find significant changes in the number of macrophages, as well as the number of DEGs in this cluster, after chronic stress. Macrophages are modulated by GCs to secrete cytokines and regulate inflammation and the immune system (53). To the best of our knowledge, this study is the first to show a significant effect of chronic stress in macrophages of the adrenal gland. In addition, our results show a global dysregulation of transcriptional activity in macrophages across all three components of the HPA axis (PVN, pituitary gland, and adrenal gland), suggesting that this cell population is part of a common, multilevel and multitissue signaling network that regulates adaptation to chronic stress.

One of the main findings from our study is the identification of a novel population of overrepresented Abcb1b+ cells within the zona fasciculata of the stressed group. The identification of this novel and specialized cell type in the adrenal gland could not have been possible using standard bulk RNA-seq methods. All previous transcriptomic studies examining the effects of chronic stress in the adrenal gland have been limited to adrenocortical, adreno-medullar, or whole tissue homogenates that average out the signature of thousands of cells, which can mask, dilute, or even distort signals of interest coming from specialized cell populations. Hence, one can expect that any cell typespecific signature of chronic stress (as is the case for zFasc1 cells) has been diluted or even lost in these studies. Here, through a series of complementary experiments, we validated this novel subpopulation of Abcb1b+ cells in the adrenal cortex, which play an important role in stress adaptation. Our experiments showed that increased mRNA expression of Abcb1b+ cells in the adrenal gland is associated with increased adrenal weight and cellular hypertrophy in the adrenal cortex of stressed mice, suggesting that chronic stress exposure causes zona fasciculata cells to enlarge and increase their expression of Abcb1b, perhaps as a mechanism to cope with the increased and sustained production of GCs in the system. The Abcb1 gene is a well-characterized efflux pump whose role is to transport substances, deemed as harmful, across membranes. However, most of the work to study this gene in psychiatry has been primarily focused on understanding the activity of the variant Abcb1a in the brain. Our single-cell analysis in combination with bulk RNA-seq data from 35 different mouse tissues showed that Abcb1b is the predominant variant in the periphery showing high expression levels among multiple tissues, particularly in the adrenal gland, suggesting that the adrenal is an important site for Abcb1 activity. Furthermore, to disentangle the effects of Abcb1a versus Abcb1b in the response to stress, we performed a series of in vitro experiments in mouse and human adrenocortical cells. Our results showed that pharmacological inhibition of Abcb1b in adrenocortical cell lines leads to a decrease in GC secretion, suggesting that modulation of Abcb1b in adrenocortical cells affects GC activity in both mice and humans. Moreover, in an attempt to translate our findings to humans, we investigated the expression of ABCB1 in adrenal cortical tissues from patients diagnosed with ACTH-dependent Cushings syndrome. These patients suffer from excessive GC secretion and adrenal hypertrophy due to a pituitary or ectopic tumor. Thus, this disease stage overlaps with the chronic activation of the HPA axis and hypersecretion of GCs in stress-related disorders. We found a significant up-regulation of ABCB1 in cases, as compared to controls. In addition to being consistent with our findings in chronically stressed mice, these results highlight the role of ABCB1 as a modulator of GC activity in the adrenal gland and postulate ABCB1 as a potential regulator of the impaired glucose metabolism associated with Cushings syndrome. Last, we investigated the relevance of our findings in depressed human patients by examining whether the ABCB1 polymorphism rs2032582 (G2677T) is associated with an altered HPA axis response in peripheral plasma samples from treatment-nave, depressed patients. In humans, the rs2032582 polymorphism has been associated with reduced protein function and activity and has been linked to major depressive disorder, suicidal ideation, and treatment response (49). Consistent with our findings in mice, adrenocortical cell lines, and adrenocortical samples from human Cushings patients, we found that, after CRF stimulation, patients with the minor (TT) allele showed a dampened cortisol but normal ACTH response, suggesting that the effects of rs2032582 on the ABCB1 gene might be taking place at the level of the adrenal gland. In addition, our results support the idea that Abcb1/ABCB1 function may regulate HPA axis response.

Together, our data offer new insights into how chronic stress regulates transcriptional activity in a multilevel, cell typespecific fashion. We identified hundreds of novel genes that are dysregulated across all tissues and levels of the HPA axis. On the basis of our intra- and intertissue analyses, we found the most profound differences due to chronic stress in the adrenal gland, which had the highest number of DEGs and the most significant changes at the cell population level. Through a series of complementary behavioral, molecular, cellular, and functional experiments, we identified a novel subpopulation of Abcb1b+ cells in the adrenal cortex, which play an important role in the adaptation process and plasticity associated with chronic stress exposure. The exact mechanism underlying the effect of ABCB1 on GC regulation and secretion in the adrenal cortex still needs to be further explored. However, previous studies have shown that transcriptional regulation of the Abcb1 genes can be mediated through a putative GC response element (GRE) identified in the promoter region of these genes in both rodents and humans (54, 55). At least in mice, this GRE binding site is only found in the promoter region of the Abcb1b variant, suggesting that Abcb1b is directly regulated by GCs in the periphery, predominantly in the adrenal glands. Therefore, we propose that the Abcb1b/ABCB1 gene and protein are involved in mediating chronic stress adaptation through regulation and control of GCs in the adrenal gland. Our findings raise the prospect that modulating ABCB1 function may be important in the treatment of patients suffering from neuropsychiatric and metabolic disorders, such as stress-related disorders and Cushings syndrome. They further suggest that adrenal ABCB1 activity could be used to stratify patients and tailor treatment strategies. Ultimately, our results provide a deeper understanding of the complex mechanisms of HPA axis regulation.

All experiments were performed in accordance with the European Communities Council Directive 2010/63/EU. All protocols were approved by the Ethics Committee for the Care and Use of Laboratory Animals of the government of Upper Bavaria, Germany. Male mice aged between 7 and 10 weeks old were used for all experiments. Mice were bred in the animal facility of the Max Planck Institute of Biochemistry (Martinsried, Germany) and group-housed (four to five mice per cage) until 1 week before the start of the experiments, when mice were single-housed. Mice were kept in individually ventilated cages (IVCs; 30 cm by 16 cm by 16 cm; 501 cm2), serviced by a central airflow system (Tecniplast, IVC Green LineGM500), according to institutional guidelines. IVCs had sufficient bedding and nesting material as well as a wooden tunnel for environmental enrichment. Animals were maintained under pathogen-free, temperature-controlled (23 1C), and constant humidity (55 10%) conditions on a 12-hour light/12-hour dark cycle (lights on at 7:00 a.m.) with food and water provided ad libitum, at the Max Planck Institute of Psychiatry (Munich, Germany).

C57BL/6N males (7 weeks old) were exposed to the CSDS paradigm for 21 consecutive days, as previously described (12). Briefly, experimental mice were introduced daily into the home cage of a dominant CD1 resident mouse, which rapidly recognized and attacked the intruders within 2 min. To avoid serious injuries, the subordinate mouse was separated immediately after being attacked by the CD1 aggressor. After the physical encounter, mice were separated by a perforated metal partition, allowing the mice to keep continuous sensory but not physical contact for the next 24 hours. Every day, for a total of 21 days, mice were defeated by another unfamiliar, CD1 resident mouse, to exclude a repeated encounter throughout the experiment. Defeat encounters were randomized, with variations in starting time (between 9:00 a.m. and 6:00 p.m.) to decrease the predictability to the stressor and minimize habituation effects. Control mice were single-housed, in the same room as the stressed mice, throughout the course of the experiment. All animals were handled daily and weighed every 4 days. Coat state was scored on a scale of 0 to 3 according to the following criteria: (0) No wounds, well-groomed and bright coat, and clean eyes; (1) no wounds, less groomed and shiny coat, OR unclean eyes; (2) small wounds, AND/OR dull and dirty coat, and not clear eyes; (3) extensive wounds, OR broad piloerection, alopecia, or crusted eyes. End point and tissue collection were performed in the morning (9:00 a.m.) and 48 hours after the last social defeat session (day 23). This was done to capture the cumulative effects of chronic stress, rather than the acute effects of the last defeat session. The SAT was conducted during the last week of the CSDS paradigm, and based on their performance, five mice from each group were selected for molecular characterization, thus avoiding potentially stress-resilient animals. For end point, all mice were deeply anesthetized with isoflurane and perfused with cold phosphate-buffered saline (PBS), and target tissues were quickly dissected for molecular experiments. Cardiac blood was collected for the assessment of basal CORT levels. Adrenal glands were dissected from fat and weighed. The brains, pituitary, and adrenal glands from selected mice were immediately processed for RNA single-cell analysis. Tissues from all remaining mice were collected for downstream validation experiments.

Social avoidance behavior was assessed with a novel CD1 mouse in a two-stage social interaction test. In the first 2.5-min test (nontarget), the experimental mouse was allowed to freely explore the open-field arena containing an empty wire mash cage against one wall of the arena (labeled as the interaction zone). In the second 2.5-min test (target), the experimental mouse was returned to the arena with an unfamiliar male CD1 mouse enclosed in the wire mash cage. The ratio between the time in the interaction zone of the nontarget trial and the time in the interaction zone of the target trial was calculated and deemed as the interaction time ratio.

Blood sampling was performed during end point (9:00 a.m.) by collecting blood from the heart of each mouse before perfusion with PBS. All blood samples were kept on ice and centrifuged at 4C, and 10 l of plasma was removed for measurement of CORT. All plasma samples were stored at 20C until CORT measurement. CORT concentrations were quantified by radioimmunoassay (RIA) using a CORT double antibody 125I RIA kit (sensitivity: 25 ng/ml; MP Biomedicals Inc.) following the manufacturers instructions. Radioactivity of the pellet was measured with a gamma counter (Wizard2 2470 Automatic Gamma Counter; Perkin Elmer). All samples were measured in duplicate, and the intra- and interassay coefficients of variation were both below 10%. Final CORT levels were derived from the standard curve.

Six different groups (each N = 5) of C57BL/6N males were exposed to a different number of social defeat sessions to assess the cumulative effects of stress and its correlation with changes in mRNA levels of Abcb1b, Sbsn, and Srd5a2. The groups were defined as follows: (i) controlno defeat, (ii) 3 days of social defeat, (iii) 5 days of social defeat, (iv) 10 days of social defeat, (v) 21 days of social defeat, and (vi) 21 days of social defeat, followed by 48 hours of recovery time. The last group was introduced to match the end point of our original chronic social defeat paradigm cohort (23 days). All mice were 7 weeks old at the beginning of the experiment. Individual social defeat encounters were carried out exactly as previously explained in the CSDS paradigm section of the methods. End point and tissue collection were performed in the morning (9:00 a.m.) of day 23. All mice were deeply anesthetized with isoflurane, and the adrenal glands were quickly dissected for molecular experiments. Adrenal glands were further dissected from fat and weighed. Trunk blood was collected for the assessment of basal CORT levels.

Tissue dissociation. Mice were anesthetized lethally using isoflurane and perfused with cold PBS to get rid of undesired blood cells in target tissues. Brains, pituitaries, and adrenal glands were quickly dissected and immediately transferred to ice-cold oxygenated artificial cerebral spinal fluid (aCSF) (brains), ice-cold Hanks balanced salt solution (HBSS) (pituitaries), or ice-cold PBS (adrenals) and kept in the same solutions during dissection and dissociation. The aCSF was oxygenated throughout the experiment with a mixture of 5% CO2 in O2. Sectioning of the brain was performed using a 0.5-mm stainless steel adult mouse brain matrix (Kent Scientific) and a Personna Double Edge Prep Razor Blade. A slide (approximately 0.58 mm Bregma to 1.22 mm Bregma) was obtained from each brain, and the extended PVN was manually dissected under the microscope. Two cell suspensions were prepared for each of the three tissues with one pool for controls and one pool for stressed mice. The PVN from five different mice was pooled and dissociated for 35 min using the Papain Dissociation System (Worthington) following the manufacturers instructions. Similarly, the pituitaries from five mice were pooled and dissociated for 15 min using papain. Last, the adrenal glands from five mice were pooled and dissociated for 55 min using a 0.2% collagenase II solution. All cell suspensions were incubated at 37C using a shaking water bath. After this, cell suspensions were filtered with 30-m filters (Partec) and kept in cold aCSF, HBSS, or PBS.

Cell capture, library preparation, and high-throughput sequencing. Cell suspensions with approximately 1,000,000 cells/l were used. Each pool was loaded onto individual lanes of a 10X Genomics Chromium chip, as per factory recommendations. For all three tissues, the control and stress cell suspensions were loaded and processed together in the same chip to avoid batch effects by condition. Reverse transcription and library preparation were performed using the 10X Genomics Single-Cell v2.0 kit following the 10X Genomics protocol. Molar concentration and fragment length of libraries were quantified by qPCR using KAPA Library Quant (Kapa Biosystems) and Bioanalyzer (Agilent High Sensitivity DNA kit), respectively. Each library was sequenced on a single lane of an Illumina HiSeq4000 System generating 100base pair paired-end reads at a depth of ~340 million reads per sample.

Preprocessing and quality control. Preprocessing of the data was done using the 10X Genomics Cell Ranger software version 2.1.1 in default mode. The 10X Genomics supplied reference data for the mm10 assembly and corresponding gene annotation was used for alignment and quantification. All further analyses were performed using Scanpy (version 1.4.4.post1) (13), following guidelines from an established best practices workflow (14). For quality control, we looked at the distribution of count depth, number of genes, and mitochondrial read fraction per sample. Because distributions were fairly homogeneous, we chose to pick the same thresholds for all samples (tissues and conditions). Specifically, we filtered out (i) cells with less than 1000 counts, (ii) less than 400 genes detected, and (iii) percentage of mitochondrial gene counts higher than 25%. In addition, genes expressed in less than 20 cells were removed as well. Quality control (QC) plots can be found in fig. S5 (E to G). This resulted in a dataset of 21,723 single cells, of which 6966 cells and 16,168 genes were from the PVN, 9879 cells and 15,437 genes were from the pituitary, and 4878 cells and 13,997 genes were from the adrenal gland. The size factors used for normalization were obtained using Scran (version 1.14.5) (56), and the data were log1 Ptransformed. Each dataset was batch-corrected using Combat (57), available in Scanpy. For each tissue, we selected the top 4000 highly variable genes using the highly_variable_genes function. Dimensionality reduction was performed using principal components analysis computed on highly variable genes and taking the first 50 PCs. Last, we computed a k-nearest neighbor graph (KNN)graph (k = 15) on the low-dimensional embedding, necessary for UMAP visualization.

Clustering, marker gene identification, and cluster annotation. Data were clustered using the Louvain (version 0.6.1) algorithm implemented in Scanpy (13). This is a graph-based clustering method that relies on the KNN-graph discussed above. We clustered at two different resolution levels (r = 0.5 and r = 1). After inspection of the cell clusters, we observed that those obtained using a finer resolution (r = 1) aligned better with our annotations and therefore used them for visualization and downstream analyses. Marker genes for each cluster were detected using a Welchs t test between cells in the cluster and all cells outside of it as reference. This was done using the rank_genes_groups function implemented in Scanpy and computed on log-normalized nonbatch-corrected data. Cell types were determined using a combination of marker genes identified from the literature and Gene Ontology for cell types using the web-based tool: mousebrain.org (58).

Differential expression analysis. Differential expression analyses were performed using MAST (59) implemented in R, which models scRNA-seq data using a generalized linear model (GLM). The computation was performed on log-normalized nonbatch-corrected data, and, for each cell cluster, we fit the following model: [Y ~ 1 + condition + n_genes], where Y is the log-normalized nonbatch-corrected data, 1 is the intercept term, condition is the covariate that accounts whether the mouse was stressed or not, and n_genes is used as a technical covariate as a proxy for technical and biological factor that might influence gene expression. The test produced a P value for each gene in each cell cluster and a q value, which is the P value after adjustment for multiple testing, using false discovery rate (FDR) correction. Furthermore, the mean expression of each gene for the two different conditions was computed.

Ambient RNA assessment. After QC analyses, we noticed the presence of highly expressed genes across all cells, despite being known marker genes of specific cell types. We noticed that most of these genes coded for neuropeptides or hormones and decided to assess whether we could explain this as ambient RNA contamination. To investigate which genes were expressed as ambient RNA, we analyzed the unfiltered datasets for the three tissues. We once again looked at the count depth distribution for what we conclude are empty droplets and selected cells with counts between 100 and 300 for the PVN, between 300 and 600 for the pituitary, and between 50 and 200 for the adrenal gland. We also removed genes that are expressed in less than 20 cells. After these steps, we obtained a dataset of 120,320 droplets and 14,129 genes for the PVN, 113,043 droplets and 13,777 genes for the pituitary, and 107,698 droplets and 11,684 genes for the adrenal gland. Because these are empty droplets and we do not expect any meaningful clustering of the data, we used a less sophisticated normalization technique, normalizing each cell by total counts over all genes, thus obtaining the same total count per cell after this step. The number of counts per cell to obtain was selected automatically as the median count per cell before normalization. For all tissues, we computed the mean expression of each gene across all droplets by condition (stress versus control). Furthermore, to exclude from our list of significantly DEGs those that are detected owing to differential ambient RNA expression, we performed differential expression testing using MAST across all droplets using the same GLM formulation defined above (note that, in our previous analysis, we tested within each cluster).

For paraffin embedding, adrenal glands were dissected and the surrounding fat was removed and fixed in 10% neutral buffered formalin (Sigma-Aldrich, HT501128) overnight at room temperature. Tissue was embedded manually over 3 days. All washes were carried out for 1 hour at room temperature unless indicated. Day 1: three times PBS, 25% EtOH, 50% EtOH, 70% EtOH, and 70% EtOH overnight at 4C. Day 2: 80% EtOH, 90% EtOH, 95% EtOH, and 100% EtOH overnight at 4C. Day 3: 100% EtOH, Neoclear (Sigma-Aldrich, 109843) I for 10 min at room temperature; Neoclear II for 10 min at 60C; Neoclear: paraffin 1:1 for 15 min at 60C, paraffin I for 1 hour at 60C, paraffin II for 1 hour at 60C, and paraffin III for 1 hour at 60C. Samples were sectioned at 5 m. RNAscope was carried out on paraffin-embedded sections with the RNAscope 2.5 HD Kit-BROWN (ACD bio 322300) assay following the manufacturers protocols, with Standard timings for retrieval and protease treatment. The following probes were used (all ACD bio): Mm-Abcb1b (422191), Mm-Sbsn (564441), Mm-Srd5a2 (431361), Hs-ABCB1 (401191), and Hs-SBSN (447411). Positive control Mm-Ppib (313911), Hs-UBC (310041), and negative control dapB (310043) were also used. Nuclei were stained with Vector Hematoxylin QS (Vector Laboratories, H-3404), and slides were mounted in VectaMount Permanent Mounting Medium (Vector Laboratories, H-5000).

Paraffin sections were deparaffinized and rehydrated as per immunohistochemistry. Slides were incubated for 30 s with Hematoxylin QS, washed with running water, incubated for 30 s with eosin, washed with running water, and mounted in VectaMount Permanent Mounting Medium.

Hematoxylin and eosin and RNAscope slides were scanned with a NanoZoomer-XR digital slide scanner (Hamamatsu). Images were processed with NanoZoomer digital pathology view (Hamamatsu), and quantification was done with Fiji.

Four areas of the same dimensions (252 252 pixels) were selected from the zona fasciculata of the cortex. Nuclei were counted, and the average cell area was calculated by dividing the number of nuclei by the total area. Values were multiplied by 1000 for graphical representation.

Quantification of messenger RNA levels of Abcb1b, Sbsn, and Srd5a2 in the adrenal glands was carried out using qRT-PCR. Total RNA was reverse-transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). RT-PCR reactions were run in triplicate using the ABI QuantStudio 6 Flex RT-PCR System and data were collected using the QuantStudio RT-PCR software (Applied Biosystems). Expression levels were calculated using the standard curve, absolute quantification method. The endogenous expressed gene Hprt was used to normalize the data. The following Taqman probes were used: Abcb1b: Mm00440736_m1, Sbsn: Mm00552057_m1, Srd5a2: Mm00446421_m1, and Hprt: Mm00446968_m1.

Mouse Y1 cells and human NCI H295R adrenocortical cells were seeded into 12-well plates and incubated overnight using Dulbeccos modified Eagles medium high glucose (4.5 g/liter) (Gibco) with 7.5% horse serum (Gibco), 2.5% fetal bovine serum (FBS) (Gibco), and 1% penicillin-streptomycin (Gibco) and RPMI 16/40 + GlutaMax (Gibco) with 10% FBS (Gibco), 1% Insulin-Transferrin-Selenium-Ethanolamine (ITS) (Thermo Fisher Scientific), and 1% penicillin-streptomycin (Gibco), respectively. In this experiment, 100,000 Y1 and NCI H295R adrenocortical cells per well were used. Cells were then stimulated for 24 hours with 10 nM forskolin and subsequently treated with different concentrations of tariquidar (0, 10, 50, 125, 250, 500, and 1000 nM) and incubated for 24 hours. Last, supernatants and cell pellets were collected and harvested for further analyses and measurement of CORT (ng/ml) and cortisol (g/liter) levels. Media CORT levels in Y1 cells were quantified by RIA using a CORT double antibody 125I RIA kit, as previously described in the animal experiments. Media cortisol levels in NCI H295R adrenocortical cells were determined using an enzyme-linked immunosorbent assay (ELISA) kit (RE52061, TECAN, IBL Hamburg, Germany). The standard range was 20 to 800 ng/ml.

The study was approved by the Ethics Committee of the University of Wuerzburg (Germany) (#88/11), and written informed consent was obtained from all subjects. Eight patients with biochemically confirmed persistent ACTH-dependent Cushings syndrome were studied. Cushings syndrome was established according to current guidelines (60). Half of the patients (n = 4) had pituitary-dependent Cushings syndrome, while, in the other patients (n = 4), ectopic Cushings syndrome had been diagnosed. The patients underwent bilateral adrenalectomy as ultima ratio to control life-threatening hypercortisolism after other therapies had failed. Formalin-fixed paraffin-embedded sections were stained as described above. The normal adrenal tissue was derived from adrenal glands removed as part of tumor nephrectomy (n = 6). They were histologically proven normal adrenal glands without neoplastic tissue.

Data of the Emory Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) (61, 62) study was used to investigate effects of the ABCB1 variant rs2032582 on HPA axis function in 154 unmedicated patients with a current Diagnostic and Statistical Manual of Mental Disorders (DSM)IV diagnosis of major depressive disorder. The PReDICT study was designed and conducted in accord with the latest version of the Declaration of Helsinki. The Emory Institutional Review Board (IRB) and the Grady Hospital Research Oversight Committee gave ethical approval for the study design, procedures, and recruitment strategies (Emory IRB numbers 00024975 and 00004719). The PReDICT study is registered at ClinicalTrials.gov Identifier: NCT03226912 and NCT00360399. DNA was extracted from whole blood, and genome-wide SNP genotyping was performed using HumanOmniExpress BeadChips. Quality control was performed in PLINK. Samples with low genotyping rate (<98%) were removed. SNPs with a high rate of missing data (>2%), significant deviation from the Hardy-Weinberg equilibrium (HWE, P < 105), or a low minor allele frequency (<5%) were excluded from further analyses. SNP genotypes were coded as 0 for major homozygotes (GG, n = 56), 1 for heterozygotes (TG, n = 74), and 2 for minor homozygotes (TT, n = 24) and did not deviate from HWE (2 = 0.27, P = 0.60). HPA axis function was assessed using the dexamethasone/corticotropin-releasing hormone (Dex/CRF) test, consisting of an oral administration of 1.5 mg of Dex at 11:00 p.m. and an infusion of ovine CRF (1 g/kg) at 3:00 p.m. on the next day. Cortisol and ACTH levels were measured from plasma samples taken immediately before CRF administration (pre-CRF) (i.e., at 3:00 p.m.) and again at 3:30 p.m. (30 min), 3:45 p.m. (45 min), 4:00 p.m. (60 min), and 4:15 p.m. (75 min). Baseline cortisol levels were available for all 154 patients with genotype data for the SNP rs2032582. Only completers were included in the analysis, so there are no dropouts in sample sizes over time. Linear regression models were used to test for effects of the SNP genotype on baseline cortisol levels using R version 3.6.2. To assess differences in cortisol and ACTH levels after the Dex/CRF test over time, linear mixed effects models with a random intercept for each patient were applied. All models included gender, age, and baseline depression severity sum scores on the 17-item Hamilton Depression Rating Scale (63) and the first five genetic ancestry (multidimensional scaling) components as covariates.

See the original post here:
Single-cell molecular profiling of all three components of the HPA axis reveals adrenal ABCB1 as a regulator of stress adaptation - Science Advances

Read More...

The Need for New Biological Targets for Therapeutic Intervention in COPD – Pulmonology Advisor

Monday, February 1st, 2021

Chronic obstructive pulmonary disease (COPD) continues to be a major cause of disability and is one of the leading causes of mortality worldwide. While there are numerous treatment options for the lung disease, the available treatments focus on symptoms secondary to inflammation, and are not curative. In a review published in the American Journal of Physiology Lung Cellular and Molecular Physiology, experts focus on potential disease-relevant pathways and emphasize the important of developing new treatments for patients with COPD.1

The objective of the review was to summarize COPD pathology, available treatment options and additional potential pathways and targets for new therapeutic development.

Cigarette smoke contains thousands of injurious agents and is the key cause of COPD worldwide as these induce tissue damage and inflammatory process leading to destruction of alveolar tissue, loss of extracellular matrix and alveolar cells, along with airway remodeling.2 As COPD may progress in patients despite smoking cessation it was suggested that persistent airway inflammation in these patients is related to repair of smoke-induced tissue damage in the airways.3 Failure to achieve normal lung function in early adulthood followed by age-appropriate rates of decline causes up to half of COPD cases.4

The 2020 Global Initiative for Chronic Obstructive Lung Disease guidelines recommend that the management strategy of COPD should be based on the assessment of symptoms and future risk of exacerbations and the main goals of pharmacological therapy for COPD are to reduce symptoms and frequency and severity of exacerbations, as well as to improve exercise tolerance and health status. However, at this point there is no evidence that any of the available medications can modify the long-term decline in lung function.5

The commonly used maintenance medications in COPD are short- and long-acting beta-2 agonists and anti-cholinergics, methylxanthines, inhaled or systemic corticosteroids, phosphodiesterase (PDE)-4 inhibitors and mucolytic agents.5 As these medications are mainly focused on relieving symptoms and reducing the risk for exacerbations, more effective treatment strategies are needed. COPD is a complex disease and precision medicine strategy, that considers biologic and psychosocial factors, may improve disease outcomes.4

New Treatment Targets

There is a real need to uncover new biology in order to advance more precision-based therapeutic strategies for patients with COPD. New disease-specific strategies in development are focusing on inflammatory pathways, hoping this will help to address disease onset. Early reports suggest there are several promising targets that can address inflammatory complications, including oxidative stress, kinase-mediates pathways, phosphodiesterase inhibitors, interleukins and chemokines.

Oxidative Stress a common denominator for aging and cellular senescence, resulting in macromolecular damage and DNA damage.2 With cigarette smoke exposure there is an increased oxidative stress, associated with an increase in Nrf2 activity which declines with the progression of COPD.6 As several studies have implicated Nrf2 in COPD pathology, this pathway is a potential important therapeutic target. Several agents may change Nrf2 expression and activity in airway cell, including aspirin-triggered resolvin D1, crocin, sulforaphane, and schisandrin B.1,6

Kinase-mediated Pathways as various kinases, including MAPK, receptor-tyrosine kinases, phosphoinositide-3-kinases, JAK, and NF-B, may induce chronic inflammation, they may serve as new targets for COPD treatment. There are several drugs that target different kinases but these are not approved for clinical use. Drugs with a more specific action, such as RV568 that inhibits p38, was well tolerated in a 14-day clinical trial and showed promising results with potent anti-inflammatory effects on cell and animal models relevant to COPD, with evidence for improvement in lung function and anti-inflammatory effects on sputum biomarkers.7

Phosphodiesterase Inhibitors inhibiting PDE leads to an increase in intracellular cAMP levels that may have anti-inflammatory effects. Roflumilast is an oral PDE-4 inhibitor already in use for more severe cases of COPD, but more potent medications are being developed, including several inhaled formulations, such as CHF6001, which was reported to have significant anti-inflammatory properties in the lungs of patients with COPD already receiving triple inhaled therapy (8). Ensifentrine is a PDE3/PDE4 inhibitor with anti-inflammatory and bronchodilator properties and when combined with short-acting bronchodilators or tiotropium caused additional improvement in lung function, reduced gas trapping, and improved airway conductance.9

Inflammatory Mediators exposure to inhaled irritants and tobacco smoke results in an increase in various interleukins (IL) that increase the number of immune cells and induce inflammatory responses. Hence, treatment directed against these mediators may reduce inflammation.1 Mepolizumab, reslizumab, and benralizumab are antibodies directed against IL-5 and its receptor and reduced eosinophil-related inflammation. These medications are approved for use for asthma, and were not effective in COPD, but may be valuable for patients with COPD with eosinophilia. Dupilumab, a monoclonal antibody directed against IL-4 and IL-13 receptor, is another potential candidate for future use. microRNAs are also involved in inflammation regulation, and miR-155 expression was shown to be increased in COPD, but at this point there are no available miRNA-based therapeutics for COPD.10

Additional Potential Treatment Targets

While multiple medications under development for COPD are focusing on the inflammatory pathways, they are not expected to reverse the lung damage. For this reason, it is important to study the upstream pathways that may help to identify strategies to reverse exiting lung damage, including targets that can lead to lung repair and regeneration.

These potential breakthrough targets may include treatments directed against mitochondrial dysfunction; structural integrity of airway epithelium such as proteins that comprise tight junctions or the extracellular matrix; various ion channels that are responsible for airway hydration; and pro-regenerative strategies, including stem cell and tissue-engineering treatments to repair lung damage.1

Animal models and 3D human-based disease models have an important role in the efforts to better understand disease process and identify specific therapeutic targets and pathways.11,12 These models improve our knowledge about the basic mechanisms underlying COPD physiology, pathophysiology and treatment. Although they can only mimic some of the features of the disease, they are valuable for further investigation of mechanisms involved in human COPD.11

Several different types of 3D cell culture models have been developed in recent years, and these have gained increasing interest in drug discovery and tissue engineering due to their evident advantages in providing more physiologically relevant information and more predictive data. Ex vivo modeling using primary human material can improve translational research activities by fostering the mechanistic understanding of human lung diseases while reducing animal usage. It is believed that using new model organisms may allow exploring new avenues and treatments approached for human disease, and these are especially promising.12

COPD is a major public health concern, and as it continues to be a global burden, the importance of developing new treatments is apparent. Current treatments are not curative, and while new strategies and drugs are in the pipeline, they still address mostly secondary inflammatory pathways of the disease. An additional major complication in COPD drug development likely comes from the essential dependency on surrogate endpoints like FEV1 to assess the impact of a therapeutic strategy. Thus, any new therapeutic strategy will ultimately require long-term studies to confirm that the surrogate endpoints accurately reflect efficacy on disease outcome, concluded the researchers.

References

1.Nguyen JMK, Robinson DN, Sidhaye VK. Why new biology must be uncovered to advance therapeutic strategies for chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol. 2021;320(1):L1-L11. doi:10.1152/ajplung.00367.2020

2.Tuder RM, Petrache I. Pathogenesis of chronic obstructive pulmonary disease. J Clin Invest. 2012;122(8):2749-55. doi:10.1172/JCI60324

3.Willemse BW, ten Hacken NH, Rutgers B, Lesman-Leegte IG, Postma DS, Timens W. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J. 2005;26(5):835-45. doi:10.1183/09031936.05.00108904

4.Sidhaye VK, Nishida K, Martinez FJ. Precision medicine in COPD: where are we and where do we need to go? Eur Respir Rev. 2018;27(149):180022. doi:10.1183/16000617.0022-2018

5.Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2020 report [Online]. Global Initiative for Chronic Obstructive Lung Disease. https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.1wms.pdf. Accessed January 25, 2021.

6.Cuadrado A, Rojo AI, Wells G, et al. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. 2019;18(4):295-317. doi:10.1038/s41573-018-0008-x

7.Charron CE, Russell P, Ito K, et al. RV568, a narrow-spectrum kinase inhibitor with p38 MAPK- and - selectivity, suppresses COPD inflammation. Eur Respir J. 2017;50(4):1700188. doi:10.1183/13993003.00188-2017

8.Singh D, Beeh KM, Colgan B, et al. Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD. Respir Res. 2019;20(1):180. doi:10.1186/s12931-019-1142-7

9.Singh D, Abbott-Banner K, Bengtsson T, Newman K. The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD. Eur Respir J. 2018;52(5):1801074. doi:10.1183/13993003.01074-2018

10.Barnes PJ. Targeting cytokines to treat asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2018;18(7):454-466. doi:10.1038/s41577-018-0006-6

11.Ghorani V, Boskabady MH, Khazdair MR, Kianmeher M. Experimental animal models for COPD: a methodological review. Tob Induc Dis. 2017;15:25. doi:10.1186/s12971-017-0130-2

12.Zscheppang K, Berg J, Hedtrich S, et al. Human pulmonary 3D models For translational research. Biotechnol J. 2018;13(1):1700341. doi:10.1002/biot.201700341

Continue reading here:
The Need for New Biological Targets for Therapeutic Intervention in COPD - Pulmonology Advisor

Read More...

Page 29«..1020..26272829


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick